

Prevalence and Characteristics of Dementia in Parkinson

Archives of Neurology

60, 387

DOI: [10.1001/archneur.60.3.387](https://doi.org/10.1001/archneur.60.3.387)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Analysis of neurological disease in four dimensions: insight from ALS-PDC epidemiology and animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2003, 27, 493-505.	2.9	26
3	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 937-941.	1.3	197
5	Basal ganglia diseases and geriatric psychiatry: a new approach. <i>Current Opinion in Psychiatry</i> , 2003, 16, 621-627.	3.1	1
7	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. <i>Brain</i> , 2004, 127, 550-560.	3.7	605
8	Cortical Lewy body disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 175-178.	0.9	15
9	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 137-145.	1.2	180
11	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	4.9	645
12	Dementia in Parkinson's disease: common and treatable. <i>Lancet Neurology</i> , The, 2004, 3, 456.	4.9	6
13	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-412.	0.8	6
14	Parkinsonian syndromes: Parkinson's disease dementia, dementia with Lewy bodies and progressive supranuclear palsy. <i>Clinical Neuroscience Research</i> , 2004, 3, 461-468.	0.8	6
15	Psychiatric aspects of Parkinson's disease. <i>Journal of Neurology</i> , 2004, 251, 795-804.	1.8	162
16	Cognitive dysfunction and dementia in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 1303-1315.	1.4	238
17	Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1487-1494.	3.3	21
18	Klinische Relevanz von PET-Untersuchungen in der Neurologie und Psychiatrie. <i>Klinische Neuroradiologie</i> , 2004, 14, 81-91.	0.9	0
19	Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. <i>Movement Disorders</i> , 2004, 19, 1043-1049.	2.2	281
20	Visual perception in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2004, 63, 2091-2096.	1.5	267
21	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-397.	0.8	1
22	Parkinsonian syndromes: Parkinson's disease dementia, dementia with Lewy bodies and progressive supranuclear palsy. <i>Clinical Neuroscience Research</i> , 2004, 3, 461-461.	0.8	1

#	ARTICLE	IF	CITATIONS
23	The neuropsychiatry of Parkinson's disease and related disorders. <i>Psychiatric Clinics of North America</i> , 2004, 27, 801-825.	0.7	87
24	Memory complaints and dementia. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 129-148.	0.7	3
25	Parkinson's Disease Dementia "A First Step?". <i>New England Journal of Medicine</i> , 2004, 351, 2547-2549.	13.9	23
27	Dementia with Lewy bodies and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, S15-S18.	1.1	78
28	Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. <i>Neuroscience Letters</i> , 2004, 354, 177-180.	1.0	65
29	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
30	Parkinson Disease: An Update. <i>Neurologist</i> , 2004, 10, 185-194.	0.4	29
31	Dementia with Lewy Bodies. <i>Clinical Neuropharmacology</i> , 2004, 27, 281-292.	0.2	9
34	Dementia in Parkinson's disease: cause and treatment. <i>Current Opinion in Neurology</i> , 2004, 17, 399-404.	1.8	71
35	Psychiatric and cognitive disorders in Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2004, 17, 197-202.	3.1	7
36	Lack of Familial Aggregation of Parkinson Disease and Alzheimer Disease. <i>Archives of Neurology</i> , 2004, 61, 1033-9.	4.9	36
37	The Rate of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1906-11.	4.9	222
38	Current World Literature. <i>Current Opinion in Psychiatry</i> , 2005, 18, 343-359.	3.1	0
39	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> , 2005, 65, 1863-1872.	1.5	4,604
40	Treatment of behavioural symptoms and dementia in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 133-146.	1.0	17
41	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 386-390.	1.0	53
42	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 201-207.	2.2	70
43	Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 418-422.	1.3	39

#	ARTICLE	IF	CITATIONS
44	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. <i>Annals of Neurology</i> , 2005, 58, 773-776.	2.8	312
45	Nonmotor complications in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, S23-S29.	2.2	140
46	Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2005, 20, 999-1005.	2.2	21
47	Apolipoprotein E ϵ 4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinations. <i>Movement Disorders</i> , 2005, 20, 989-994.	2.2	55
48	A systematic review of prevalence studies of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1255-1263.	2.2	1,060
49	How to diagnose dementia with Lewy bodies: State of the art. <i>Movement Disorders</i> , 2005, 20, S11-S20.	2.2	304
50	Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. <i>Journal of Neurology</i> , 2005, 252, 1345-1352.	1.8	129
51	Rivastigmine for dementia associated with Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 263-265.	2.0	0
52	Other Dementias. , 0, , 1111-1133.		0
53	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
55	Role of Neuropsychiatric Assessment in Diagnosis and Research. , 2005, , 163-183.		0
57	Benefits of rivastigmine on attention in dementia associated with Parkinson disease. <i>Neurology</i> , 2005, 65, 1654-1656.	1.5	148
58	Cognitive status correlates with neuropathologic stage in Parkinson disease. <i>Neurology</i> , 2005, 64, 1404-1410.	1.5	509
59	Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 903-904.	0.9	12
60	Temporal lobe atrophy on MRI in Parkinson disease with dementia. <i>Neurology</i> , 2005, 64, 861-865.	1.5	193
61	A systematic review of nutritional risk factors of Parkinson's disease. <i>Nutrition Research Reviews</i> , 2005, 18, 259-282.	2.1	40
62	Atypical Parkinsonian Disorders. , 2005, , .		10
63	Visual dysfunction in Parkinson disease without dementia. <i>Neurology</i> , 2005, 65, 1907-1913.	1.5	268

#	ARTICLE	IF	CITATIONS
64	The national service framework for long term conditions: a novel approach for a "new style" NSF. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 901-902.	0.9	10
65	Corpus Callosum in Neurodegenerative Diseases: Findings in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 345-351.	0.7	47
66	Dimensions of Executive Function in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 140-144.	0.7	83
67	Ultrafast magnetic resonance imaging protocols in stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 905-905.	0.9	7
68	Cerebral Blood Flow in Parkinson's Disease, Dementia with Lewy Bodies, and Alzheimer's Disease according to Three-Dimensional Stereotactic Surface Projection Imaging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 266-275.	0.7	38
69	Surgery for movement disorders: new applications?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 904-904.	0.9	4
70	Cognitive Predictors of Dementia in Parkinson's Disease: A Community-Based, 4-Year Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 149-154.	1.2	158
71	Prognosis of Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 1265.	4.9	198
72	Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). <i>Age and Ageing</i> , 2005, 34, 268-273.	0.7	45
73	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. <i>Brain</i> , 2005, 128, 1259-1266.	3.7	133
74	Rivastigmine for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 563-580.	1.4	35
75	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. <i>Brain</i> , 2005, 128, 1267-1276.	3.7	201
76	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 844-851.	0.6	105
77	Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety. <i>Psychiatric Clinics of North America</i> , 2005, 28, 941-983.	0.7	12
78	Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. <i>Neurology</i> , 2005, 65, 1716-1722.	1.5	340
79	Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 311-315.	1.1	20
80	Parkinson's Disease and Sleep. <i>Neurologic Clinics</i> , 2005, 23, 1187-1208.	0.8	43
81	Treatment of advanced Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1181-1197.	1.4	41

#	ARTICLE	IF	CITATIONS
82	Management of Parkinson's Disease Dementia. <i>Drugs and Aging</i> , 2006, 23, 807-822.	1.3	19
83	Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia. <i>Pharmacoeconomics</i> , 2006, 24, 93-106.	1.7	14
84	Cognitive Deficits and Psychosis in Parkinson's Disease. <i>CNS Drugs</i> , 2006, 20, 477-505.	2.7	115
85	Rivastigmine. <i>CNS Drugs</i> , 2006, 20, 739-747.	2.7	7
86	Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): [RETIRED]. <i>Neurology</i> , 2006, 66, 996-1002.	1.5	484
87	Excessive daytime sleepiness in Parkinson disease: Is it the drugs or the disease?. <i>Neurology</i> , 2006, 67, 853-858.	1.5	177
88	Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 585-589.	0.9	342
89	Resting state oscillatory brain dynamics in Parkinson's disease: An MEG study. <i>Clinical Neurophysiology</i> , 2006, 117, 2521-2531.	0.7	173
90	Nonmotor symptoms of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1811-1822.	1.4	48
92	Cognitive, Affective, and Psychiatric Features of Parkinson's Disease. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 773-796.	1.0	30
93	Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function. <i>Biological Psychiatry</i> , 2006, 59, 898-907.	0.7	258
94	Functional imaging of sequence learning in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 72-77.	0.3	45
95	Cognitive decline correlates with neuropathological stage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 255-258.	0.3	157
96	Differences and similarities in the neuropsychological profile of dementia with Lewy bodies and Alzheimer's disease in the early stage. <i>Journal of the Neurological Sciences</i> , 2006, 248, 120-123.	0.3	32
97	Are dementia and depression in Parkinson's disease related?. <i>Journal of the Neurological Sciences</i> , 2006, 248, 138-142.	0.3	43
98	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006, 27, 433-438.	1.5	58
99	Neuropharmacological Treatment of Mental Dysfunction in Parkinson's Disease. <i>Behavioural Neurology</i> , 2006, 17, 43-51.	1.1	13
101	Becoming a person again. <i>Nursing Standard (Royal College of Nursing (Great Britain): 1987)</i> , 2006, 20, 69-69.	0.1	0

#	ARTICLE	IF	CITATIONS
103	Providing quality care for residents with Parkinson's disease. <i>Nursing and Residential Care</i> , 2006, 8, 275-277.	0.1	1
104	Clinical Features of Severe Dementia: Staging. , 2006, , 83-115.		9
105	Plasma Homocysteine Levels and Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2006, 29, 305-311.	0.2	42
106	Impact of Functional Age on the Use of Dopamine Agonists in Patients With Parkinson Disease. <i>Neurologist</i> , 2006, 12, 214-223.	0.4	20
107	Cognitive Change in Parkinson Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 302-310.	0.6	51
108	Non-Motor Aspects of Parkinson's Disease. <i>CNS Spectrums</i> , 2006, 11, 541-554.	0.7	43
110	Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease. <i>Annals of General Psychiatry</i> , 2006, 5, 12.	1.2	2
111	Parkinson's disease with dementia and dementia with Lewy body disease: two syndromes, the same disease?. <i>Psychogeriatrics</i> , 2006, 6, S30-S34.	0.6	2
112	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1186-1202.	1.7	183
113	Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. <i>Movement Disorders</i> , 2006, 21, 624-631.	2.2	145
114	Diagnosis and management of Parkinson's disease. <i>The Prescriber</i> , 2006, 17, 56-63.	0.1	0
115	Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 1154-1159.	1.8	20
116	Parkinson's disease and dementia. <i>Neurological Sciences</i> , 2006, 27, s40-s43.	0.9	36
117	Epidemiology of Parkinson's disease. <i>Lancet Neurology</i> , The, 2006, 5, 525-535.	4.9	3,329
118	Demonstration of cognitive decline in Parkinson's disease using the Cambridge Cognitive Assessment (Revised) (CAMCOG-R). <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 977-982.	1.3	17
119	Hippocampal neuron and glial cell numbers in Parkinson's disease—A stereological study. <i>Hippocampus</i> , 2006, 16, 826-833.	0.9	63
120	Comorbid conditions associated with Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2006, 21, 446-455.	2.2	100
121	Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. <i>Movement Disorders</i> , 2006, 21, 456-461.	2.2	109

#	ARTICLE	IF	CITATIONS
122	Visual rating of white matter hyperintensities in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 223-229.	2.2	97
123	Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. <i>Movement Disorders</i> , 2006, 21, 148-158.	2.2	312
124	Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006, 21, 337-342.	2.2	103
125	Predictors of weight loss in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 930-936.	2.2	116
126	Deep brain stimulation: Postoperative issues. <i>Movement Disorders</i> , 2006, 21, S219-S237.	2.2	276
127	Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. <i>Movement Disorders</i> , 2006, 21, 1343-1349.	2.2	541
128	Side and type of motor symptom influence cognition in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1947-1953.	2.2	69
129	Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. <i>Movement Disorders</i> , 2006, 21, 2170-2174.	2.2	22
130	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	2.8	240
132	Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 566-567.	0.9	20
133	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 254-259.	0.9	235
134	Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1136-1142.	0.9	141
135	Cognitive changes in Parkinson's disease during subthalamic stimulation: a clinicopathologic study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 565-566.	0.9	7
136	Cognitive and psychiatric aspects of Parkinson's disease: treatment recommendations. <i>Aging Health</i> , 2006, 2, 87-99.	0.3	0
137	Clinical phenotype of Parkinson disease dementia. <i>Neurology</i> , 2006, 67, 1605-1611.	1.5	222
138	Familial Occurrence of Dementia and Parkinsonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 288-295.	0.7	22
139	Can amantadine therapy delay the onset of dementia in Parkinson's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 648-649.	2.7	8
141	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 699-710.	1.4	6

#	ARTICLE	IF	CITATIONS
142	REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. <i>Neurology</i> , 2007, 69, 1843-1849.	1.5	264
143	NICE guideline for Parkinson's disease. <i>Age and Ageing</i> , 2007, 36, 240-242.	0.7	36
145	Clinical correlates of Lewy-body-related disorders: splitting and lumping or lumping and splitting?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 308-309.	2.7	0
146	Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies. <i>American Journal of Psychiatry</i> , 2007, 164, 1491-1498.	4.0	102
147	Dementia with Lewy Bodies. <i>Seminars in Neurology</i> , 2007, 27, 042-047.	0.5	82
148	Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 250-251.	2.7	1
149	Rivastigmine and Parkinson dementia complex. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 817-829.	0.9	12
150	Developing the NICE/SCIE Guidelines for Dementia Care: The Challenges of Enhancing the Evidence Base for Social and Health Care. <i>British Journal of Social Work</i> , 2007, 37, 475-490.	0.9	13
151	Cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1182-1187.	0.9	204
152	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. <i>Archives of Neurology</i> , 2007, 64, 1436.	4.9	143
153	Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. <i>Practical Neurology</i> , 2007, 7, 374-382.	0.5	79
154	Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 351-367.	0.7	11
155	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
156	Cognitive Changes in Parkinson's Disease Patients with Visual Hallucinations. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 281-288.	0.7	99
157	Imaging in dementia. <i>Imaging</i> , 2007, 19, 133-141.	0.0	0
158	Catechol O-Methyltransferase val158met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 4832-4838.	1.7	175
159	Functional Ability Correlates with Cognitive Impairment in Parkinson's Disease and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 327-334.	0.7	38
161	Chapter 9 Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Blue Books of Neurology</i> , 2007, , 216-238.	0.1	1

#	ARTICLE	IF	CITATIONS
162	Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 231.	1.0	28
163	Non-motor dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 323-332.	1.1	171
164	Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. <i>Neurobiology of Aging</i> , 2007, 28, 568-578.	1.5	109
165	La Maladie de Parkinson. , 2007, , 11-88.		1
166	A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1457-1463.	1.4	39
168	Rivastigmine in Parkinson's Disease Dementia. <i>Drugs and Aging</i> , 2007, 24, 255-259.	1.3	4
169	FMR1 Alleles in Parkinson's Disease: Relation to Cognitive Decline and Hallucinations, A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 89-92.	1.2	34
170	Die Parkinson-Krankheit. , 2007, , .		12
171	Distinguishing Lewy body dementias from Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1499-1516.	1.4	26
172	Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1693-1729.	1.4	17
173	Dementia with Lewy bodies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 531-548.	1.0	21
174	Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 83, 401-419.	1.0	13
175	Old age and Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 427-444.	1.0	12
176	Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 36-42.	0.9	401
177	Management of the behavioral aspects of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 711-725.	1.4	17
178	MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. <i>Journal of the Neurological Sciences</i> , 2007, 257, 97-104.	0.3	68
179	Non-motor Symptoms of Parkinson's Disease. <i>International Journal of Gerontology</i> , 2007, 1, 53-64.	0.7	44
180	The Degenerative Dementias. , 2007, , 699-733.		4

#	ARTICLE	IF	CITATIONS
181	Rivastigmine in Dementia Associated with Parkinson's Disease and Alzheimer's Disease: Similarities and Differences. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 509-519.	1.2	50
182	Declínio cognitivo e demência associados à doença de Parkinson: características clínicas e tratamento. <i>Revista De Psiquiatria Clinica</i> , 2007, 34, 176-183.	0.6	18
184	Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 529-535.	1.3	104
185	Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 141-144.	2.2	49
186	Fatigue in Parkinson's disease: A review. <i>Movement Disorders</i> , 2007, 22, 297-308.	2.2	294
187	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
188	Cognitive dysfunction and dementia in Parkinson disease. <i>Movement Disorders</i> , 2007, 22, S358-S366.	2.2	188
189	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. <i>Movement Disorders</i> , 2007, 22, 2418-2425.	2.2	84
190	Distinguishing dementia with Lewy bodies from dementia occurring in Parkinson's disease: A literature review. <i>Australasian Journal on Ageing</i> , 2007, 26, 58-63.	0.4	3
191	The patient with Parkinson's disease: Part I?Treating the motor symptoms; Part II?Treating the nonmotor symptoms. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 179-197.	1.4	23
192	A UK survey of treatment of dementia in Parkinson's disease. <i>Progress in Neurology and Psychiatry</i> , 2007, 11, 8-12.	0.4	0
193	Autonomic and Cognitive dysfunction in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2007, 17, 93-98.	1.4	55
194	Gait and posture impairment, parkinsonism and cognitive decline in older people. <i>Journal of Neural Transmission</i> , 2007, 114, 1355-1361.	1.4	40
195	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007, 254, 38-45.	1.8	141
196	Dementia in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 41-48.	1.8	8
197	Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history. <i>Neurogenetics</i> , 2007, 8, 263-270.	0.7	19
198	Neuropsychological Characteristics of Dementia with Lewy Bodies and Parkinson's Disease with Dementia: Differentiation, Early Detection, and Implications for "Mild Cognitive Impairment" and Biomarkers. <i>Neuropsychology Review</i> , 2008, 18, 103-119.	2.5	161
199	Cognitive impairment in 873 patients with idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 255-264.	1.8	242

#	ARTICLE	IF	CITATIONS
200	Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. <i>Journal of Neurology</i> , 2008, 255, 1324-1331.	1.8	123
201	Epidemiology of Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 18-32.	1.8	314
202	Lewy body dementia and Parkinson's disease with dementia. <i>Journal of Neurology</i> , 2008, 255, 39-47.	1.8	45
203	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. <i>Movement Disorders</i> , 2008, 23, 837-844.	2.2	1,779
204	The montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1043-1046.	2.2	299
205	Levodopa unresponsive symptoms in Parkinson disease. <i>Movement Disorders</i> , 2008, 23, S521-S533.	2.2	132
206	Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. <i>Movement Disorders</i> , 2008, 23, 1130-1136.	2.2	212
207	Predictors and course of health-related quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1420-1427.	2.2	150
208	REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A two-year follow up. <i>Movement Disorders</i> , 2008, 23, 1441-1445.	2.2	85
209	Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 255-259.	1.0	55
210	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. <i>Neurobiology of Disease</i> , 2008, 31, 41-45.	2.1	66
211	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. <i>Advances in Anatomy, Embryology and Cell Biology</i> , 2008, , .	1.0	85
213	Cognitive and behavioural impairment in Parkinson's disease. <i>International Review of Psychiatry</i> , 2008, 20, 364-373.	1.4	10
214	Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. <i>Neuroscience Letters</i> , 2008, 448, 20-23.	1.0	54
215	Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. <i>Neurobiology of Aging</i> , 2008, 29, 1027-1039.	1.5	146
216	Psychosocial issues in young-onset Parkinson's disease: Current research and challenges. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 143-150.	1.1	34
217	Clinical features at first visit and rapid disease progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 431-435.	1.1	19
218	Uric acid associates with cognition in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 576-578.	1.1	56

#	ARTICLE	IF	CITATIONS
219	Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 465-470.	1.1	57
220	Grey matter atrophy in early versus late dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 620-625.	1.1	18
221	Relationship of phosphorylated α -synuclein and tau accumulation to $A\beta$ deposition in the cerebral cortex of dementia with Lewy bodies. <i>Experimental Neurology</i> , 2008, 210, 409-420.	2.0	90
222	Is malfunction of the ubiquitin proteasome system the primary cause of α -synucleinopathies and other chronic human neurodegenerative disease?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 683-690.	1.8	26
223	Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. <i>Alzheimer's and Dementia</i> , 2008, 4, 421-427.	0.4	67
224	Dementia and survival in Parkinson disease. <i>Neurology</i> , 2008, 70, 1017-1022.	1.5	403
225	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
226	Cognitive Dysfunctions in Mild Parkinson's Disease Dementia: Comparison with Patients Having Mild Alzheimer's Disease and Normal Controls. <i>European Neurology</i> , 2008, 59, 49-54.	0.6	17
227	A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson's Disease versus Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 301-308.	0.7	40
228	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 330-338.	0.7	48
229	Cognitive Impairment in Parkinson's Disease and Dementia with Lewy Bodies: A Spectrum of Disease. <i>NeuroSignals</i> , 2008, 16, 24-34.	0.5	46
230	Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1318-1323.	0.9	69
231	Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory. <i>Journal of Neuroscience</i> , 2008, 28, 7797-7807.	1.7	62
233	Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.	1.5	73
234	Potential therapeutic targets for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 425-436.	1.5	15
235	Rivastigmine in Parkinson's disease dementia. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1181-1188.	1.4	9
236	Sex and Gender in Older Adults' Experience of Parkinson's Disease. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2008, 63, S42-S48.	2.4	45
237	Patients Homozygous and Heterozygous for SNCA Duplication in a Family With Parkinsonism and Dementia. <i>Archives of Neurology</i> , 2008, 65, 514.	4.9	117

#	ARTICLE	IF	CITATIONS
238	Antiparkinsonian Medication and Pathological Gambling. <i>CNS Drugs</i> , 2008, 22, 407-416.	2.7	40
239	Brain N-acetylaspartate is Reduced in Parkinson Disease With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 54-60.	0.6	38
240	Nondemented Parkinson Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 87-91.	0.5	14
241	Comparison of Quantitative EEGs Between Parkinson Disease and Age-Adjusted Normal Controls. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 361-366.	0.9	66
242	Dementia with Parkinson's disease: Clinical diagnosis, neuropsychological aspects and treatment. <i>Dementia E Neuropsychologia</i> , 2008, 2, 261-266.	0.3	2
243	Rivastigmine for the treatment of dementia associated with Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, Volume 3, 775-783.	1.0	7
244	Cognitive decline tracks motor progression and not disease duration in Parkinson patients. <i>Neuropsychiatric Disease and Treatment</i> , 2008, Volume 3, 955-958.	1.0	17
246	Mental health in Parkinson's disease: Supporting patients and carers. <i>British Journal of Neuroscience Nursing</i> , 2009, 5, 253-259.	0.1	1
247	Dementia and mild cognitive impairment in patients with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 423-427.	0.3	22
248	CaracterizaÃ§Ã£o dos distÃºrbios cognitivos na DoenÃ§a de Parkinson. <i>Revista CEFAC: AtualizaÃ§Ã£o CientÃfica Em Fonoaudiologia</i> , 2009, 11, 251-257.	0.2	16
249	Treatment strategies for nonmotor manifestations of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 773-784.	0.9	10
250	The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009, 72, S1-136.	1.5	685
251	Cognitive Characteristics Associated with Mild Cognitive Impairment in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 121-129.	0.7	53
252	The Contribution of Executive Control on Verbal-Learning Impairment in Patients with Parkinson's Disease with Dementia and Alzheimer's Disease. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 237-244.	0.3	15
253	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2009, 73, 1738-1745.	1.5	946
254	Magnetic Resonance Imaging in Lewy Body Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 493-506.	0.7	82
255	A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 18-23.	0.9	54
256	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. <i>Neurology</i> , 2009, 73, 1469-1477.	1.5	136

#	ARTICLE	IF	CITATIONS
257	APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009, 22, 166-170.	1.2	51
258	Depressive Symptoms in Parkinson Disease Correlate With Impaired Global and Specific Cognitive Performance. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009, 22, 223-227.	1.2	28
259	Deep Brain Stimulation for Patients With Advanced Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1985.	3.8	1
260	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. <i>Neurobiology of Disease</i> , 2009, 35, 296-301.	2.1	15
261	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. <i>Lancet Neurology</i> , The, 2009, 8, 464-474.	4.9	1,367
262	Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. <i>Annals of Neurology</i> , 2008, 64, S81-S92.	2.8	122
263	A unique case of cortical myoclonus sensitive to visual stimuli in the peripersonal space. <i>Movement Disorders</i> , 2009, 24, 422-425.	2.2	1
264	Responsiveness to levodopa in epsilon-sarcoglycan deletions. <i>Movement Disorders</i> , 2009, 24, 425-428.	2.2	43
265	Cognitive decline in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 605-608.	2.2	51
266	Genetic association study of the P-glycoprotein ATPase <i>ATP13A2</i> in late-onset Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 429-433.	2.2	13
267	Does auditory rhythmical cueing improve gait in people with Parkinson's disease and cognitive impairment? A Feasibility study. <i>Movement Disorders</i> , 2009, 24, 839-845.	2.2	116
268	Zonisamide for essential tremor: An evaluator-blinded study. <i>Movement Disorders</i> , 2009, 24, 437-440.	2.2	42
269	Validity of the Cornell scale for depression in dementia in Parkinson's disease with and without cognitive impairment. <i>Movement Disorders</i> , 2009, 24, 433-437.	2.2	17
270	Haplotype analysis of the <i>PARK 11</i> gene, <i>GIGYF2</i> , in sporadic Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 448-452.	2.2	19
271	Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. <i>Movement Disorders</i> , 2009, 24, 445-447.	2.2	49
272	A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: Description of clinical features and implications for genotype-phenotype correlations. <i>Movement Disorders</i> , 2009, 24, 441-445.	2.2	64
273	<i>FGF20</i> and Parkinson's disease: No evidence of association or pathogenicity via α -synuclein expression. <i>Movement Disorders</i> , 2009, 24, 455-459.	2.2	41
274	Traditional Chinese medicine on four patients with Huntington's disease. <i>Movement Disorders</i> , 2009, 24, 453-455.	2.2	20

#	ARTICLE	IF	CITATIONS
275	Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. <i>Movement Disorders</i> , 2009, 24, S754-9.	2.2	75
276	Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2203-2210.	2.2	163
277	Clinical measures of progression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S671-6.	2.2	77
278	Cross-sectional and longitudinal studies of three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1475-1480.	2.2	12
279	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration" [¹⁸ F]FDG-PET. <i>Movement Disorders</i> , 2009, 24, 1504-1511.	2.2	46
280	MRI and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S748-53.	2.2	66
281	Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1941-1948.	2.2	24
282	Beyond tremor and rigidity: non-motor features of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2009, 116, 1483-1492.	1.4	76
283	The morbid anatomy of dementia in Parkinson's disease. <i>Acta Neuropathologica</i> , 2009, 118, 587-598.	3.9	77
284	Morphological differences in Parkinson's disease with and without rest tremor. <i>Journal of Neurology</i> , 2009, 256, 256-263.	1.8	108
285	Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with "Normal" Global Cognition According to Mini-Mental State Examination Score. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 304-308.	1.3	270
286	The effect of onset age on the clinical features of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 450-456.	1.7	151
287	Prevalence of dementia subtypes: A 30-year retrospective survey of neuropathological reports. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, 146-149.	1.4	118
288	Benefits of physical exercise on executive functions in older people with Parkinson's disease. <i>Brain and Cognition</i> , 2009, 69, 435-441.	0.8	179
289	Brain magnetic resonance imaging (MRI) in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 165-174.	1.1	52
290	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 226-231.	1.1	163
291	Does laterality of motor impairment tell us something about cognition in Parkinson disease?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 315-317.	1.1	39
292	Parkinson's disease dementia " A diminished role for the Lewy body. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 572-575.	1.1	17

#	ARTICLE	IF	CITATIONS
293	â€œParkinson-dementiaâ€•diseases: A comparison by double tracer SPECT studies. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 762-766.	1.1	25
294	Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies. <i>Neuroscience Letters</i> , 2009, 461, 12-15.	1.0	42
295	Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism. <i>American Journal of Medicine</i> , 2009, 122, 614-622.	0.6	19
296	Cognitive decline in Parkinsonâ€™s disease: A prospective longitudinal study. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 426-437.	1.2	134
297	Non-motor extranigral signs and symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S6-S12.	1.1	104
298	Non-motor features of Parkinson's disease: depression and dementia. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S87-S92.	1.1	45
299	The clinical progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S28-S32.	1.1	123
300	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. <i>Brain</i> , 2009, 132, 2958-2969.	3.7	842
301	Memory Complaints and Dementia. <i>Medical Clinics of North America</i> , 2009, 93, 389-406.	1.1	6
302	Parkinson Disease With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 295-297.	0.6	183
303	The Auditory System Involvement in Parkinson Disease: Electrophysiological and Neuropsychological Correlations. <i>Journal of Clinical Neurophysiology</i> , 2009, 26, 430-437.	0.9	29
304	Dementia treatment. , 0, , 213-253.		2
305	DÃ©mence parkinsonienne etÃ©mence Ã©corps deÃ©Lewy. <i>Neurologie Com</i> , 2009, 1, 149-153.	0.0	0
307	Patient selection: When to consider deep brain stimulation for patients with Parkinson's disease, essential tremor, or dystonia. , 0, , 4-19.		0
309	Biomarker discovery for Alzheimerâ€™s disease, frontotemporal lobar degeneration, and Parkinsonâ€™s disease. <i>Acta Neuropathologica</i> , 2010, 120, 385-399.	3.9	79
310	Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2010, 257, 1073-1082.	1.8	216
311	Late-stage Parkinsonâ€™s disease: the Barcelona and Lisbon cohort. <i>Journal of Neurology</i> , 2010, 257, 1524-1532.	1.8	106
312	Has drug therapy changed the natural history of Parkinsonâ€™s disease?. <i>Journal of Neurology</i> , 2010, 257, 262-267.	1.8	12

#	ARTICLE	IF	CITATIONS
313	Neurodegenerative dementia and Parkinsonism. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 37-44.	1.5	6
314	Cognitive Impairments in Progression of Parkinson's Disease. <i>Neuroscience and Behavioral Physiology</i> , 2010, 40, 61-67.	0.2	15
315	Pilot study of a three-step diagnostic pathway for young and old patients with Parkinson's disease dementia: screen, test and then diagnose. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 258-265.	1.3	26
316	Glycoproteomics in neurodegenerative diseases. <i>Mass Spectrometry Reviews</i> , 2010, 29, 79-125.	2.8	99
317	Parkinson's disease: 10 years of progress, 1997-2007. <i>Movement Disorders</i> , 2010, 25, S2-14.	2.2	40
318	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 687-695.	2.2	145
319	Association between cognition and function in patients with Parkinson disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 1170-1176.	2.2	131
320	Everyday reasoning abilities in persons with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2756-2761.	2.2	14
321	Parkinson's disease dementia can be easily detected in routine clinical practice. <i>Movement Disorders</i> , 2010, 25, 2769-2776.	2.2	36
322	α -synuclein induced synapse damage is enhanced by amyloid- β 1-42. <i>Molecular Neurodegeneration</i> , 2010, 5, 55.	4.4	43
323	A deformation-based morphometry study of patients with early-stage Parkinson's disease. <i>European Journal of Neurology</i> , 2010, 17, 314-320.	1.7	80
324	Familial associations of Alzheimer disease and essential tremor with Parkinson disease. <i>European Journal of Neurology</i> , 2010, 17, 871-878.	1.7	25
325	Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 38-43.	1.0	40
326	REM sleep behavior disorder. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 15-54.	1.8	531
327	The Treatment of Cognitive Impairment Associated with Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 672-678.	2.1	17
328	The Epidemiology of Dementia Associated with Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 633-639.	2.1	253
329	Profile of Cognitive Impairment in Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 640-645.	2.1	156
331	Facteurs de risque de démence dans une population de personnes âgées gaulaises. <i>African Journal of Neurological Sciences</i> , 2010, 28, .	0.0	4

#	ARTICLE	IF	CITATIONS
332	Dementia in Parkinson's Disease. Blue Books of Neurology, 2010, , 188-212.	0.1	1
333	CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology, 2010, 75, 1055-1061.	1.5	315
334	Environmental Factors and Parkinson's Disease. Blue Books of Neurology, 2010, , 113-131.	0.1	0
335	Influence of White Matter Hyperintensities on the Cognition of Patients With Parkinson Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 227-233.	0.6	84
336	Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: Effects on Activities of Daily Living. Dementia and Geriatric Cognitive Disorders, 2010, 29, 510-515.	0.7	23
337	Cognitive Deterioration Rates in Patients with Parkinson's Disease from Northeastern China. Dementia and Geriatric Cognitive Disorders, 2010, 30, 64-70.	0.7	7
338	Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 407-413.	0.9	21
339	A 12-Year Population-Based Study of Psychosis in Parkinson Disease. Archives of Neurology, 2010, 67, 996-1001.	4.9	323
340	What predicts mortality in Parkinson disease?. Neurology, 2010, 75, 1270-1276.	1.5	252
341	Cognitive Performance in Nondemented Nonpsychotic Parkinson Disease Patients With or Without a History of Depression Prior to the Onset of Motor Symptoms. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 15-26.	1.2	17
342	β -synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. International Psychogeriatrics, 2010, 22, 321-327.	0.6	20
343	Nephrilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid- β 42 Levels in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 22, 933-938.	1.2	23
344	Utility of the NeuroTrax Computerized Battery for Cognitive Screening in Parkinson's Disease: Comparison with the MMSE and the MoCA. International Journal of Neuroscience, 2010, 120, 538-543.	0.8	24
345	Parkinsonism and Other Movement Disorders. , 2010, , 511-519.		1
346	The decrease of β -synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain, 2010, 133, 3724-3733.	3.7	35
347	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.9	10
348	Development of Parkinson's disease biomarkers. Expert Review of Neurotherapeutics, 2010, 10, 1811-1825.	1.4	9
349	Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?. Journal of the Neurological Sciences, 2010, 289, 23-26.	0.3	20

#	ARTICLE	IF	CITATIONS
350	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 18-22.	0.3	384
351	Olfactory loss and nigrostriatal dopaminergic denervation in the elderly. <i>Neuroscience Letters</i> , 2010, 484, 163-167.	1.0	47
352	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	1.1	45
353	The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson's Disease. <i>Psychosomatics</i> , 2010, 51, 474-479.	2.5	64
355	The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 937-942.	1.2	32
356	Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 650-657.	0.9	126
357	Imaging cognitive and behavioral symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1827-1838.	1.4	18
358	Developing predictive biomarkers for dementia of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1661-1663.	1.4	0
359	Cataract and cognitive impairment: a review of the literature. <i>British Journal of Ophthalmology</i> , 2011, 95, 17-23.	2.1	50
360	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1033-1037.	0.9	151
361	Diseases. , 2011, , 189-348.		0
362	The importance of non-motor disturbances to quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 12-16.	0.3	129
363	Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. <i>Journal of the Neurological Sciences</i> , 2011, 310, 112-117.	0.3	26
364	Cerebral basis of visual hallucinations in Parkinson's disease: Structural and functional MRI studies. <i>Journal of the Neurological Sciences</i> , 2011, 310, 79-81.	0.3	46
365	French translation and normation of the Parkinson neuropsychometric dementia assessment (PANDA). <i>Journal of the Neurological Sciences</i> , 2011, 310, 189-193.	0.3	6
366	Dopamine-depletion and increased α -synuclein load induce degeneration of cortical cholinergic fibers in mice. <i>Journal of the Neurological Sciences</i> , 2011, 310, 90-95.	0.3	25
367	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
369	How might physical activity benefit patients with Parkinson disease?. <i>Nature Reviews Neurology</i> , 2011, 7, 528-534.	4.9	227

#	ARTICLE	IF	CITATIONS
370	High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β -amyloid in Parkinson disease. <i>Neuroscience Letters</i> , 2011, 487, 169-173.	1.0	18
371	Assessing executive function in Parkinson disease: The Alternating Names Test. Part I. Reliability, validity, and normative data. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 100-105.	1.1	9
372	Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 61-64.	1.1	64
373	Uric acid and cognition in Parkinsonâ€™s disease: A follow-up study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 333-337.	1.1	25
374	Mild cognitive impairment and cognitive reserve in Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 579-586.	1.1	86
375	Dementia associated with Parkinsonâ€™s disease: Applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 621-624.	1.1	61
376	Neuropsychiatric symptoms. , 2011, , 45-56.		1
377	Parkinson's Disease Dementia and Potential Therapeutic Strategies. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 32-44.	1.9	38
378	Dopaminergic imaging: clinical utility now and in the future. <i>International Psychogeriatrics</i> , 2011, 23, S32-S40.	0.6	9
379	Communication Impairments in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-2.	0.6	2
380	Language Processing in Parkinson's Disease Patients Without Dementia. , 2011, , .		6
381	New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. <i>Parkinson's Disease</i> , 2011, 2011, 1-12.	0.6	11
382	Neuropsychological Deficits in Initial Parkinsonâ€™s Disease. , 2011, , .		0
383	Dementia in Parkinson's disease: a Brazilian sample. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 733-738.	0.3	9
385	High-Level Language Production in Parkinson's Disease: A Review. <i>Parkinson's Disease</i> , 2011, 2011, 1-12.	0.6	68
386	Dementia in Parkinson's Disease: A Clinical Review. <i>American Journal of Neuroscience</i> , 2011, 2, 35-47.	0.4	3
387	Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis. <i>Archives of Neurology</i> , 2011, 68, 899.	4.9	105
388	Potential of Tissue Engineering and Neural Stem Cells in the Understanding and Treatment of Neurodegenerative Diseases. , 2011, , 321-345.		0

#	ARTICLE	IF	CITATIONS
389	Exercise alleviates Parkinsonism: clinical and laboratory evidence. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 73-84.	1.0	47
390	Efficacy and safety of choline alfoscerate (cereton) in patients with parkinson's disease with cognitive impairments. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 47-51.	0.2	5
391	Mild cognitive impairment exists in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 1179-1183.	1.4	7
392	Is all cognitive impairment in Parkinson's disease "mild cognitive impairment?". <i>Journal of Neural Transmission</i> , 2011, 118, 1185-1190.	1.4	32
394	Dementia in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2011, 13, 242-254.	0.7	22
396	Patterns of comorbidity in community-dwelling older people hospitalised for fall-related injury: A cluster analysis. <i>BMC Geriatrics</i> , 2011, 11, 45.	1.1	63
397	Silent saliva aspiration in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 138-141.	2.2	70
398	Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. <i>Movement Disorders</i> , 2011, 26, 157-161.	2.2	50
399	How well do caregivers detect mild cognitive change in Parkinson's disease?. <i>Movement Disorders</i> , 2011, 26, 161-164.	2.2	27
400	Estimation of skeletal muscle energy metabolism in Machado-Joseph disease using ³¹ P-MR spectroscopy. <i>Movement Disorders</i> , 2011, 26, 165-168.	2.2	3
401	Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. <i>Movement Disorders</i> , 2011, 26, 169-173.	2.2	38
402	Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study. <i>Movement Disorders</i> , 2011, 26, 173-176.	2.2	22
403	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , 2011, 26, 176-181.	2.2	43
404	Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. <i>Movement Disorders</i> , 2011, 26, 142-147.	2.2	48
405	Tardive dyskinesia and other movement disorders secondary to aripiprazole. <i>Movement Disorders</i> , 2011, 26, 147-152.	2.2	73
406	Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study. <i>Movement Disorders</i> , 2011, 26, 153-157.	2.2	83
407	Uric acid as a potential disease modifier in patients with multiple system atrophy. <i>Movement Disorders</i> , 2011, 26, 1533-1536.	2.2	31
408	Neuropsychological functioning in Parkinson's disease: Differential relationships with self-reported sleep-wake disturbances. <i>Movement Disorders</i> , 2011, 26, 1537-1541.	2.2	47

#	ARTICLE	IF	CITATIONS
409	The economic impact of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1541-1544.	2.2	100
410	The role of the inferior frontal gyri in cognitive processing of patients with Parkinson's disease: A pilot rTMS study. <i>Movement Disorders</i> , 2011, 26, 1545-1548.	2.2	41
411	Parkinson's disease: The quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011, 26, 1022-1031.	2.2	349
412	A new diagnostic test to distinguish tremulous Parkinson's disease from advanced essential tremor. <i>Movement Disorders</i> , 2011, 26, 1548-1552.	2.2	51
413	Cardiac autonomic denervation in Parkinson's disease is linked to REM sleep behavior disorder. <i>Movement Disorders</i> , 2011, 26, 1529-1533.	2.2	73
414	A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1552-1555.	2.2	26
415	Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. <i>Movement Disorders</i> , 2011, 26, 1443-1450.	2.2	56
416	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
417	The interplay of cholinergic function, attention, and falls in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2496-2503.	2.2	193
418	Seize the day. <i>Neurology</i> , 2011, 77, 94-95.	1.5	5
419	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1562.	4.9	180
420	Cognition and driving in older persons. <i>Swiss Medical Weekly</i> , 2011, 140, w13136.	0.8	28
421	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. <i>Brain</i> , 2011, 134, 1493-1505.	3.7	497
422	Validity of the Mattis Dementia Rating Scale to Detect Mild Cognitive Impairment in Parkinson's Disease and REM Sleep Behavior Disorder. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 210-217.	0.7	45
423	Clinical overview and phenomenology of movement disorders. , 2011, , 1-35.		7
424	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0
426	Parkinson's Disease and Dementia: A Longitudinal Study (DEMPARK). <i>Neuroepidemiology</i> , 2011, 37, 168-176.	1.1	47
427	Nonmotor Disturbances in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2011, 8, 95-108.	0.8	42

#	ARTICLE	IF	CITATIONS
428	Republished review: Cataract and cognitive impairment: a review of the literature. Postgraduate Medical Journal, 2011, 87, 636-642.	0.9	6
429	Nonmotor Manifestations in Parkinson Disease. Neurologist, 2012, 18, 1-16.	0.4	69
430	Motor Symptoms at Onset of Parkinson Disease and Risk for Cognitive Impairment and Depression. Cognitive and Behavioral Neurology, 2012, 25, 115-120.	0.5	21
431	Lower cognitive performance in healthy G2019S <i>LRRK2</i> mutation carriers. Neurology, 2012, 79, 1027-1032.	1.5	75
433	Caregiver Burden in Parkinson Disease With Dementia Compared to Alzheimer Disease in Korea. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 222-226.	1.2	32
434	An evaluation of the impact of<i>MAPT</i>,<i>SNCA</i>and<i>APOE</i>on the burden of Alzheimer's and Lewy body pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 424-429.	0.9	50
435	Efficacy of a Multimodal Cognitive Rehabilitation Including Psychomotor and Endurance Training in Parkinson's Disease. Journal of Aging Research, 2012, 2012, 1-15.	0.4	57
436	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinsonâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2012, 34, 312-318.	0.7	24
437	Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 315-321.	0.9	51
438	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinsonâ€™s Disease. Frontiers in Neurology, 2012, 3, 159.	1.1	31
439	Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 100-106.	1.2	45
440	Sentence production in Parkinson disease: Effects of conceptual and task complexity. Applied Psycholinguistics, 2012, 33, 225-251.	0.8	44
441	Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice. DMM Disease Models and Mechanisms, 2013, 6, 171-83.	1.2	18
442	The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.. Neuropsychology, 2012, 26, 368-384.	1.0	30
443	Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?. Brain, 2012, 135, 3206-3226.	3.7	421
444	New concepts in the early and preclinical detection of Parkinsonâ€™s disease: therapeutic implications. Expert Review of Neurotherapeutics, 2012, 12, 1429-1438.	1.4	18
445	Drug treatments for the neuropsychiatric complications of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 1439-1449.	1.4	23
446	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurology, The, 2012, 11, 697-707.	4.9	432

#	ARTICLE	IF	CITATIONS
447	Neuropathologic substrates of Parkinson disease dementia. <i>Annals of Neurology</i> , 2012, 72, 587-598.	2.8	401
448	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012, 531, 1-4.	1.0	7
449	Cognitive impairments in Parkinson's disease. <i>Aging and Mental Health</i> , 2012, 16, 529-536.	1.5	3
450	The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons. <i>Neurobiology of Aging</i> , 2012, 33, 423.e27-423.e36.	1.5	32
451	Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. <i>Neurobiology of Aging</i> , 2012, 33, 428.e1-428.e5.	1.5	41
452	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. <i>Neurobiology of Aging</i> , 2012, 33, 629.e5-629.e18.	1.5	73
453	A β -amyloid deposition in patients with Parkinson disease at risk for development of dementia. <i>Neurology</i> , 2012, 79, 1161-1167.	1.5	94
454	Relationship between changes of body mass index (BMI) and cognitive decline in Parkinson's disease (PD). <i>Archives of Gerontology and Geriatrics</i> , 2012, 55, 70-72.	1.4	52
455	Sentence processing in Lewy body spectrum disorder: The role of working memory. <i>Brain and Cognition</i> , 2012, 78, 85-93.	0.8	18
456	Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia. <i>European Neurology</i> , 2012, 68, 137-143.	0.6	25
457	Sleep disturbance in Parkinson disease. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2012, 3, 53-61.	0.7	9
458	Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. <i>Brain Research</i> , 2012, 1476, 58-70.	1.1	112
459	Affective symptoms and cognitive functions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 317, 97-102.	0.3	52
460	Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 323, 158-161.	0.3	12
461	A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson's disease in China. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1497-1500.	0.8	38
462	Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 407-417.	0.8	9
464	Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. <i>The Cochrane Library</i> , 2014, 2014, CD006504.	1.5	224
465	Parkinson's Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 389-455.	1.0	283

#	ARTICLE	IF	CITATIONS
466	The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 3338-3347.	0.7	60
467	Visual hallucinations: a review for ophthalmologists. <i>Expert Review of Ophthalmology</i> , 2012, 7, 471-479.	0.3	0
468	Clinical aspects of palliative care in advanced Parkinson's disease. <i>BMC Palliative Care</i> , 2012, 11, 20.	0.8	23
469	Current status of clinical trials of neural transplantation in Parkinson's disease. <i>Progress in Brain Research</i> , 2012, 200, 169-198.	0.9	27
470	A Review of Dual-Task Walking Deficits in People with Parkinson's Disease: Motor and Cognitive Contributions, Mechanisms, and Clinical Implications. <i>Parkinson's Disease</i> , 2012, 2012, 1-14.	0.6	229
471	Epidemiology of Psychiatric Symptoms in Parkinson's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 1-12.	0.2	5
472	Parkinson's Disease with Dementia. <i>Advances in Biological Psychiatry</i> , 2012, , 103-124.	0.2	2
473	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S385-S396.	1.2	5
474	Behavioral and Psychological Symptoms in Patients with Parkinson's Disease According to Cognitive Function. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 104.	0.4	1
475	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012, 135, 170-180.	3.7	149
476	Psychosis in Parkinson's disease without dementia: Common and comorbid with other non-motor symptoms. <i>Movement Disorders</i> , 2012, 27, 858-863.	2.2	109
477	Brain amyloid and cognition in Lewy body diseases. <i>Movement Disorders</i> , 2012, 27, 965-973.	2.2	150
478	Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1129-1136.	2.2	87
479	Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1173-1177.	2.2	38
480	Cognitive Deficits in Early Parkinson's Disease: New Areas of Research. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2012, 1, 39-44.	0.7	3
481	CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. <i>Journal of Neural Transmission</i> , 2012, 119, 861-875.	1.4	16
482	New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. <i>Neurogenetics</i> , 2012, 13, 61-72.	0.7	17
483	Difficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder. <i>Brain and Language</i> , 2012, 120, 52-60.	0.8	23

#	ARTICLE	IF	CITATIONS
484	Impairments of speech fluency in Lewy body spectrum disorder. <i>Brain and Language</i> , 2012, 120, 290-302.	0.8	47
485	A large study reveals no association between APOE and Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 46, 389-392.	2.1	99
486	Cognitive impairment and dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 46, 590-596.	2.1	198
487	The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 1100-1107.	1.7	31
488	Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. <i>Movement Disorders</i> , 2012, 27, 8-30.	2.2	356
489	Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253.	2.2	51
490	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
491	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , 2012, 27, 727-734.	2.2	49
492	Predictive value of dopamine transporter SPECT imaging with [¹²³ I]PE2I in patients with subtle parkinsonian symptoms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 242-250.	3.3	28
493	Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 364-371.	1.3	9
494	Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. <i>Nature Reviews Neuroscience</i> , 2013, 14, 626-636.	4.9	673
495	Drug Therapy for the Elderly. , 2013, , .		22
496	Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies. <i>Neurological Sciences</i> , 2013, 34, 613-619.	0.9	51
497	Association of Cerebrospinal Fluid β -Amyloid 1-42, T-tau, P-tau ₁₈₁ , and α -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 1277-87.	4.5	318
498	The Movement Disorders Society criteria for the diagnosis of Parkinson's disease dementia: their usefulness and limitations in elderly patients. <i>Journal of Neurology</i> , 2013, 260, 2569-2579.	1.8	17
499	Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. <i>Neuroscience Letters</i> , 2013, 541, 111-115.	1.0	43
500	Mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 517-521.	1.4	14
501	Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. <i>Cortex</i> , 2013, 49, 1833-1843.	1.1	71

#	ARTICLE	IF	CITATIONS
502	Dementia in Parkinson's disease: Usefulness of the pill questionnaire. <i>Movement Disorders</i> , 2013, 28, 1832-1837.	2.2	10
503	Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1972-1979.	2.2	110
504	Advanced Parkinson's disease: Clinical characteristics and treatment (part 1). <i>Neurología (English)</i> 10, 267-276.	0.2	26
505	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. <i>Journal of Comparative Neurology</i> , 2013, 521, 4339-4355.	0.9	47
506	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2013, 24, 267-78.	1.4	152
507	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 101-113.	1.2	79
508	New Pharmacological Options for Treating Advanced Parkinson's Disease. <i>Clinical Therapeutics</i> , 2013, 35, 1640-1652.	1.1	36
509	Executive dysfunction in Parkinson's disease: A review. <i>Journal of Neuropsychology</i> , 2013, 7, 193-224.	0.6	387
511	Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. <i>Neurobiology of Aging</i> , 2013, 34, 408-418.	1.5	130
512	Impairment of the septal cholinergic neurons in MPTP-treated A30P α -synuclein mice. <i>Neurobiology of Aging</i> , 2013, 34, 589-601.	1.5	16
513	Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. <i>Neurology</i> , 2013, 80, 85-91.	1.5	149
514	Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	1.7	290
515	Objective Evidence of Autonomic Dysfunction and the Role of Stress in the Gulf War Syndrome. <i>JAMA Neurology</i> , 2013, 70, 158.	4.5	3
516	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. <i>JAMA Neurology</i> , 2013, 70, 223.	4.5	302
517	Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 227-231.	1.1	50
518	Impairment of script comprehension in Lewy body spectrum disorders. <i>Brain and Language</i> , 2013, 125, 330-343.	0.8	5
519	Prevalence of Parkinson Disease and Parkinson Disease Dementia in Community Nursing Homes. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 529-535.	0.6	14
520	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013, 9, 609-614.	0.4	24

#	ARTICLE	IF	CITATIONS
522	Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?. <i>Movement Disorders</i> , 2013, 28, 425-438.	2.2	81
523	Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 627-633.	1.4	48
524	The spectrum of cognitive disorders in Parkinson's disease: A data-driven approach. <i>Movement Disorders</i> , 2013, 28, 183-189.	2.2	51
525	A review of cognitive and other non-motor problems in Parkinson's disease. <i>Aging Health</i> , 2013, 9, 89-102.	0.3	0
526	The more cortical amyloid β , the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. <i>Movement Disorders</i> , 2013, 28, 263-264.	2.2	2
527	Prognosis of Mild Cognitive Impairment in Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 580.	4.5	270
528	Managing palliative care in Parkinson's disease from diagnosis to end-stage disease: what the clinician should know. <i>Neurodegenerative Disease Management</i> , 2013, 3, 169-183.	1.2	6
529	Handbook of Parkinson's Disease. , 2013, , .		14
530	Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 225-240.	0.6	28
531	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	1.3	54
532	Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1072-1076.	2.8	39
533	Cognitive correlates of visual hallucinations in non-demented Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 795-799.	1.1	33
534	Cortical thinning is associated with disease stages and dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 875-882.	0.9	155
538	Gray matter atrophy distinguishes between Parkinson disease motor subtypes. <i>Neurology</i> , 2013, 80, 1476-1484.	1.5	130
539	The Impact of MRI White Matter Hyperintensities on Dementia in Parkinson's Disease in Relation to the Homocysteine Level and Other Vascular Risk Factors. <i>Neurodegenerative Diseases</i> , 2013, 12, 1-12.	0.8	45
540	White-Matter Changes Correlate with Cognitive Functioning in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2013, 4, 37.	1.1	53
541	Usefulness of Cube Copying in Evaluating Clinical Profiles of Patients with Parkinson Disease. <i>Cognitive and Behavioral Neurology</i> , 2013, 26, 140-145.	0.5	8
542	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 774-783.	0.9	199

#	ARTICLE	IF	CITATIONS
543	Cognitive Change in Newly-Diagnosed Patients with Parkinson's Disease: A 5-Year Follow-up Study. Journal of the International Neuropsychological Society, 2013, 19, 695-708.	1.2	74
544	Very Long-Standing Parkinson's Disease. European Neurology, 2013, 70, 172-174.	0.6	1
545	Lower Urinary Tract Symptoms in Men With Parkinson Disease. Journal of Neuroscience Nursing, 2013, 45, 382-392.	0.7	14
546	Erken Evre Parkinson Hastalığında Motor Olmayan Semptomların Değerlendirilmesi. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2013, 19, 97-103.	0.1	4
547	Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life. Journal of the American Geriatrics Society, 2013, 61, 1714-1721.	1.3	62
549	Parkinson's disease: pathology, anatomy, and behavior. , 0, , 14-24.		0
550	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
552	Imaging and behavior in Parkinson's disease: structural imaging. , 0, , 73-88.		0
554	Parkinson's disease dementia. , 0, , 177-191.		0
557	The genetics of behavior and cognition in Parkinson's disease. , 0, , 25-39.		0
558	Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia. Journal of Parkinson's Disease, 2013, 3, 69-76.	1.5	38
559	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. BMC Neurology, 2013, 13, 140.	0.8	31
561	Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Movement Disorders, 2013, 28, 1360-1369.	2.2	54
562	Effect of different exercise programs on the psychological and cognitive functions of people with Parkinson's disease. Motriz Revista De Educacao Fisica, 2013, 19, 597-604.	0.3	6
563	Análisis del desempeño cognitivo de los enfermos con Parkinson: importancia del nivel educativo. Revista De La Asociación Española De Neuropsiquiatría, 2013, 33, 245-255.	0.1	1
564	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). Neuropsychiatric Disease and Treatment, 2013, 9, 927.	1.0	33
566	Neural and behavioral substrates of subtypes of Parkinson's disease. Frontiers in Systems Neuroscience, 2013, 7, 117.	1.2	24
567	Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Frontiers in Systems Neuroscience, 2013, 7, 118.	1.2	73

#	ARTICLE	IF	CITATIONS
568	Visual Hallucinations in PD and Lewy Body Dementias: Old and New Hypotheses. Behavioural Neurology, 2013, 27, 479-493.	1.1	68
569	Other Dementias. , 2013, , .		0
570	What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinsonâ€™s disease? Is the Significance Diagnostic or Prognostic?. Experimental Neurobiology, 2014, 23, 352-364.	0.7	16
571	Active Aging for Individuals with Parkinsonâ€™s Disease: Definitions, Literature Review, and Models. Parkinson's Disease, 2014, 2014, 1-8.	0.6	8
572	Mortality in Levodopa-Treated Parkinson's Disease. Parkinson's Disease, 2014, 2014, 1-8.	0.6	22
573	Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors. Clinical Interventions in Aging, 2014, 9, 275.	1.3	19
574	Quantitative Electroencephalogram Analysis in Parkinsonâ€™s Disease. Neuroscience and Biomedical Engineering, 2014, 1, 83-91.	0.4	0
575	The utility of the Edinburgh Depression Scale as a screening tool for depression in Parkinson's disease. International Journal of Geriatric Psychiatry, 2014, 29, 1286-1293.	1.3	3
576	Dementia and Systemic Disease. , 2014, , 1263-1277.		0
577	Â–Amyloid in CSF: A window into Parkinson disease dementia. Neurology, 2014, 82, 1758-1759.	1.5	2
578	A clinical profile of patients with Parkinsonâ€™s disease and psychosis. Annals of Indian Academy of Neurology, 2014, 17, 187.	0.2	13
579	A voxel based comparative analysis using magnetization transfer imaging and T1-weighted magnetic resonance imaging in progressive supranuclear palsy. Annals of Indian Academy of Neurology, 2014, 17, 193.	0.2	8
580	Genetic impact on cognition and brain function in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	3.7	127
581	Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology, 2014, 82, 263-270.	1.5	80
582	The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease. European Journal of Neurology, 2014, 21, 922.	1.7	55
583	Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1405-1410.	1.1	31
584	Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Movement Disorders, 2014, 29, 351-359.	2.2	124
585	What light have resting state fMRI studies shed on cognition and mood in Parkinsonâ€™s disease?. Journal of Clinical Movement Disorders, 2014, 1, 4.	2.2	3

#	ARTICLE	IF	CITATIONS
586	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86
587	Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 405.	1.0	66
588	<i>APOE</i> , <i>MAPT</i> , and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	4.5	172
589	Associations Between Cognitive and Gait Performance During Single- and Dual-Task Walking in People With Parkinson Disease. <i>Physical Therapy</i> , 2014, 94, 757-766.	1.1	57
590	Dementia and Cognitive Impairment in Patients With Parkinson's Disease From India. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 630-636.	0.9	18
591	Course of psychiatric symptoms and global cognition in early Parkinson disease. <i>Neurology</i> , 2014, 83, 1096-1103.	1.5	116
592	Assessment and management of dementia in the general hospital setting. <i>Reviews in Clinical Gerontology</i> , 2014, 24, 205-218.	0.5	9
593	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 530.	0.4	18
594	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	1.4	3
595	Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. <i>Brain</i> , 2014, 137, 849-859.	3.7	135
596	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 651-662.	2.2	41
597	The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , 2014, 29, 608-621.	2.2	107
598	Predictors of Parkinson's disease dementia: Towards targeted therapies for a heterogeneous disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S104-S107.	1.1	19
599	Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson's and Alzheimer's disease patients. <i>Geriatrics and Gerontology International</i> , 2014, 14, 259-266.	0.7	71
600	Treatment of Psychosis and Dementia in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2014, 16, 281.	0.7	103
601	Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. <i>Neurobiology of Aging</i> , 2014, 35, 990-1001.	1.5	39
602	CSF A β ₄₂ predicts early-onset dementia in Parkinson disease. <i>Neurology</i> , 2014, 82, 1784-1790.	1.5	135
603	Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1203-1208.	1.1	83

#	ARTICLE	IF	CITATIONS
604	Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 999-1003.	1.1	24
605	Chrelin: A link between ageing, metabolism and neurodegenerative disorders. <i>Neurobiology of Disease</i> , 2014, 72, 72-83.	2.1	65
606	Advocacy, education, and the role of not-for-profit organizations in Lewy body dementias. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 59.	3.0	2
607	Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 472.	2.0	33
609	Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 5431-5441.	1.9	30
610	Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 980-985.	1.1	98
611	Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 580-586.	0.6	19
612	Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1739-1743.	1.5	44
613	Insulin resistance and gray matter volume in neurodegenerative disease. <i>Neuroscience</i> , 2014, 270, 139-147.	1.1	56
614	Non-motor symptoms in Chinese Parkinson's disease patients. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 751-754.	0.8	15
615	Virtual, Augmented Reality and Serious Games for Healthcare 1. <i>Intelligent Systems Reference Library</i> , 2014, , .	1.0	81
616	Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , 2015, 30, 1657-1663.	2.2	143
617	Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 659-667.	1.5	66
618	The Aeromedical Implications of Parkinson's Disease. <i>Aerospace Medicine and Human Performance</i> , 2015, 86, 1046-1051.	0.2	1
619	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's Disease. <i>The Cochrane Library</i> , 0, , .	1.5	7
620	Effect of virtual reality dance exercise on the balance, activities of daily living, and depressive disorder status of Parkinson's disease patients. <i>Journal of Physical Therapy Science</i> , 2015, 27, 145-147.	0.2	126
621	Memory for gist and detail information in patients with Parkinson's disease. <i>BMJ Open</i> , 2015, 5, e009795.	0.8	19
622	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015, 5, 971-981.	1.5	15

#	ARTICLE	IF	CITATIONS
623	Patient selection: When to consider deep brain stimulation for patients with Parkinson's disease, essential tremor, or dystonia. , 0, , 5-30.		0
624	Advances in the treatment of cognitive impairment in <sc>P</sc>arkinson's disease. Movement Disorders, 2015, 30, 1471-1489.	2.2	65
625	Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. Movement Disorders, 2015, 30, 912-918.	2.2	91
626	Prevalence and Risk Factors of Cognitive Impairment in Parkinson Disease. Medicine (United States), 2015, 94, e782.	0.4	4
627	Hypometabolism in Posterior and Temporal Areas of the Brain is Associated with Cognitive Decline in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 569-574.	1.5	37
629	Aberrant Brain Network Efficiency in Parkinson's Disease Patients with Tremor: A Multi-Modality Study. Frontiers in Aging Neuroscience, 2015, 7, 169.	1.7	32
630	Electroconvulsive therapy in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2015, 73, 856-860.	0.3	19
631	Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients. PLoS ONE, 2015, 10, e0142582.	1.1	37
632	Rapid Screening for Cognitive Impairment in Parkinson's Disease: A Pilot Study. Parkinson's Disease, 2015, 2015, 1-6.	0.6	6
633	Visual Hallucinations as Incidental Negative Effects of Virtual Reality on Parkinson's Disease Patients: A Link with Neurodegeneration?. Parkinson's Disease, 2015, 2015, 1-6.	0.6	9
634	Addenbrooke's Cognitive Examination and Individual Domain Cut-Off Scores for Discriminating between Different Cognitive Subtypes of Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	0.6	18
635	Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease. Behavioural Neurology, 2015, 2015, 1-10.	1.1	39
636	Development of Tablet Device App for Parkinson's Disease Patients's Continuous Self-Monitoring and Management. Neuroscience and Biomedical Engineering, 2015, 3, 40-48.	0.4	2
637	Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes. Clinical and Translational Imaging, 2015, 3, 57-64.	1.1	22
638	Syntax, action verbs, action semantics, and object semantics in Parkinson's disease: Dissociability, progression, and executive influences. Cortex, 2015, 69, 237-254.	1.1	147
639	Parkinson's Disease Dementia. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 53-77.	0.3	0
640	Hearing and music in dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 129, 667-687.	1.0	15
641	Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 862-870.	1.1	51

#	ARTICLE	IF	CITATIONS
642	Î±-Synuclein-Induced Synapse Damage in Cultured Neurons Is Mediated by Cholesterol-Sensitive Activation of Cytoplasmic Phospholipase A2. <i>Biomolecules</i> , 2015, 5, 178-193.	1.8	25
644	Homocysteine and Dementia. , 2015, , 611-621.		4
645	Rare variants in Î²-Amyloid precursor protein (APP) and Parkinsonâ€™s disease. <i>European Journal of Human Genetics</i> , 2015, 23, 1328-1333.	1.4	50
646	The significance of motor (A)symmetry in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 379-385.	2.2	41
647	The ethics of deep brain stimulation (DBS). <i>Medicine, Health Care and Philosophy</i> , 2015, 18, 475-485.	0.9	21
648	A neurophysiological profile in Parkinsonâ€™s disease with mild cognitive impairment and dementia in China. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 981-985.	0.8	23
649	Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease. <i>Regenerative Medicine</i> , 2015, 10, 431-446.	0.8	59
650	Baseline and longitudinal grey matter changes in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. <i>Brain</i> , 2015, 138, 2974-2986.	3.7	188
651	Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. <i>Neurobiology of Aging</i> , 2015, 36, 1519-1528.	1.5	35
652	Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review. <i>Movement Disorders</i> , 2015, 30, 928-935.	2.2	159
653	Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Longâ€™standing Model. <i>Brain Pathology</i> , 2015, 25, 377-390.	2.1	76
654	Phosphorylated Î±-synuclein in Parkinsonâ€™s disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7.	2.4	74
655	Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. <i>European Journal of Radiology</i> , 2015, 84, 1318-1324.	1.2	74
656	Review of delirium in patients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2015, 262, 2401-2410.	1.8	82
657	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 692-697.	1.1	99
658	Precision medicine: Clarity for the clinical and biological complexity of Alzheimerâ€™s and Parkinsonâ€™s diseases. <i>Journal of Experimental Medicine</i> , 2015, 212, 601-605.	4.2	34
659	Personality and Dementia. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 210-214.	0.5	27
660	Biomarkers of cognitive decline in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 431-443.	1.1	71

#	ARTICLE	IF	CITATIONS
661	Cognitive Decline and Dementia in Parkinson's Disease. , 2015, , 113-125.		0
662	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders, 2015, 30, 919-927.	2.2	244
663	Are Dental Implants the Answer to Tooth Loss in Patients with Parkinson's Disease?. Primary Dental Journal, 2015, 4, 35-41.	0.3	5
664	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurology, 2015, 72, 1175.	4.5	148
665	Designing for and with People with Parkinson's. , 2015, , .		31
666	Depression and dementia. A review. European Geriatric Medicine, 2015, 6, 479-486.	1.2	40
667	Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats. Neuroscience, 2015, 307, 51-63.	1.1	3
668	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.5	197
669	Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention – A Comparison with Parkinson's Disease. Neuropsychology Review, 2015, 25, 424-438.	2.5	42
670	The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nature Reviews Neurology, 2015, 11, 25-40.	4.9	211
671	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). Movement Disorders, 2015, 30, 229-237.	2.2	402
672	Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression. Cellular and Molecular Life Sciences, 2015, 72, 773-797.	2.4	85
673	Neuropsychiatric Symptoms of Movement Disorders. Neuropsychiatric Symptoms of Neurological Disease, 2015, , .	0.3	0
674	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 147-154.	1.8	12
675	Cognitive Impairment in Parkinson's Disease: Historical Review, Past, and Present. , 2016, , .		0
676	The Chronic Exercise-Cognition Interaction and Parkinson Disease. , 2016, , 321-343.		2
677	Management of cognitive impairment in Parkinson's disease. , 0, , 111-121.		0
678	Event-Related Potentials in Parkinson's Disease Patients with Visual Hallucination. Parkinson's Disease, 2016, 2016, 1-7.	0.6	4

#	ARTICLE	IF	CITATIONS
679	Insula Volume and Salience Network Are Associated with Memory Decline in Parkinson Disease: Complementary Analyses of Voxel-Based Morphometry versus Volume of Interest. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	9
680	Structural Neuroimaging Markers of Cognitive Decline in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	11
681	Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-13.	0.6	53
682	The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	9
683	Parkinson's Disease and Cognitive Impairment. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	50
684	Subcortical Volumes Differ in Parkinson's Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 356.	1.0	45
685	Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014. <i>Parkinson's Disease</i> , 2016, 2016, 1-19.	0.6	20
686	Î±-synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 991-999.	2.8	85
687	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016, 31, 1095-1102.	2.2	254
688	Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. <i>Human Brain Mapping</i> , 2016, 37, 968-977.	1.9	40
689	Lewy and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 451-462.	1.8	26
690	Different PD-MCI criteria and risk of dementia in Parkinson's disease: 4-year longitudinal study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15027.	2.5	55
691	The effect of aerobic exercise on dual-task gait in individuals with Parkinson's disease. <i>International Journal of Therapy and Rehabilitation</i> , 2016, 23, 524-532.	0.1	1
692	“Under pressure”: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	0.9	75
693	Converging mediators from immune and trophic pathways to identify Parkinson disease dementia. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e193.	3.1	12
694	Aerobic Exercise Improves Mood, Cognition, and Language Function in Parkinson's Disease: Results of a Controlled Study. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 878-889.	1.2	75
695	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. <i>Scientific Reports</i> , 2016, 6, 26145.	1.6	24
697	Concomitant administration of quetiapine/rivastigmine in Parkinson's disease dementia (PDD). <i>European Neuropsychopharmacology</i> , 2016, 26, S657-S658.	0.3	0

#	ARTICLE	IF	CITATIONS
699	Apolipoprotein E ϵ 4 does not affect cognitive performance in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 112-116.	1.1	22
700	Saliency and Default Mode Network Coupling Predicts Cognition in Aging and Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 205-215.	1.2	64
701	Movement Disorders. <i>Medical Clinics of North America</i> , 2016, 100, 733-761.	1.1	9
702	How close are we to individualized medicine for Parkinson's disease?. Expert Review of Neurotherapeutics, 2016, 16, 815-830.	1.4	21
703	Robustness of reliable change indices to variability in Parkinson's disease with mild cognitive impairment. <i>Applied Neuropsychology Adult</i> , 2016, 23, 399-402.	0.7	6
704	Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review". <i>CNS Drugs</i> , 2016, 30, 1007-1008.	2.7	1
705	Epidemiology of Parkinson Disease. <i>Neurologic Clinics</i> , 2016, 34, 955-965.	0.8	242
706	Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia. <i>Journal of the Neurological Sciences</i> , 2016, 370, 82-87.	0.3	48
707	Optic nerve integrity as a visuospatial cognitive predictor in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 41-45.	1.1	7
709	Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up. <i>Journal of Parkinson's Disease</i> , 2016, 6, 793-804.	1.5	5
710	Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 370, 100-106.	0.3	34
711	Motor symptoms in Parkinson's disease: A unified framework. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 727-740.	2.9	231
712	Progresión clínic de la enfermedad de Parkinson: análisis retrospectivo en un consultorio especializado en trastornos del movimiento. <i>Neurología Argentina</i> , 2016, 8, 258-262.	0.1	1
713	Cognitive decline in Parkinson's disease: the complex picture. <i>Npj Parkinson's Disease</i> , 2016, 2, 16018.	2.5	96
715	Education and risk of incident dementia during the premotor and motor phases of essential tremor (NEDICES). <i>Medicine (United States)</i> , 2016, 95, e4607.	0.4	8
717	Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. <i>Journal of Nanobiotechnology</i> , 2016, 14, 41.	4.2	59
718	ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 363-379.	0.2	14
719	Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 585-594.	0.9	14

#	ARTICLE	IF	CITATIONS
720	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 668-675.	2.2	31
721	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016, 31, 1066-1070.	2.2	34
722	Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. <i>Movement Disorders</i> , 2016, 31, 709-714.	2.2	47
723	Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 861-881.	2.2	118
724	Cortical Lewy bodies and A β burden are associated with prevalence and timing of dementia in Lewy body diseases. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 436-450.	1.8	67
725	Deep brain stimulation of the subthalamic nucleus alters frontal activity during spatial working memory maintenance of patients with Parkinson's disease. <i>Neurocase</i> , 2016, 22, 369-378.	0.2	8
726	Alterations in conflict monitoring are related to functional connectivity in Parkinson's disease. <i>Cortex</i> , 2016, 82, 277-286.	1.1	8
727	Overlap between Parkinson disease and Alzheimer disease in <i>ABCA7</i> functional variants. <i>Neurology: Genetics</i> , 2016, 2, e44.	0.9	31
728	Epidemiology of Parkinson's disease. <i>Revue Neurologique</i> , 2016, 172, 14-26.	0.6	292
729	Value of cerebrospinal fluid α -synuclein species as biomarker in Parkinson's diagnosis and prognosis. <i>Biomarkers in Medicine</i> , 2016, 10, 35-49.	0.6	51
730	Clinical Implications of the National Institute of Neurological Disorders and Stroke Criteria for Diagnosing Psychosis in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 26-31.	0.9	8
731	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 535.	4.5	136
732	Interrelations between cognitive dysfunction and motor symptoms of Parkinson's disease: behavioral and neural studies. <i>Reviews in the Neurosciences</i> , 2016, 27, 535-548.	1.4	23
733	Cholinergic imaging in dementia spectrum disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1376-1386.	3.3	87
734	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
735	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
736	Brain Connectivity Alterations Are Associated with the Development of Dementia in Parkinson's Disease. <i>Brain Connectivity</i> , 2016, 6, 216-224.	0.8	30
737	Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 1-8.	1.1	52

#	ARTICLE	IF	CITATIONS
738	Nrf2â€‘ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. , 2016, 157, 84-104.		463
739	Dementia with Lewy bodies: The emerging role of primary care. <i>European Journal of General Practice</i> , 2016, 22, 53-57.	0.9	2
740	CSF Î²-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 88-92.	1.1	89
741	Neurophysiological biomarkers for Lewy body dementias. <i>Clinical Neurophysiology</i> , 2016, 127, 349-359.	0.7	40
742	Onset and progression factors in Parkinsonâ€™s disease: A systematic review. <i>NeuroToxicology</i> , 2017, 61, 132-141.	1.4	30
743	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
744	Comorbid conditions associated with Parkinson's disease: A longitudinal and comparative study with Alzheimer disease and control subjects. <i>Journal of the Neurological Sciences</i> , 2017, 373, 210-215.	0.3	29
745	Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal Î², and AÎ² as well as dementia-risk in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 223-229.	0.3	14
746	Associations of hippocampal subfields in the progression of cognitive decline related to Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 14, 37-42.	1.4	73
747	Improved cognition while cycling in Parkinsonâ€™s disease patients and healthy adults. <i>Brain and Cognition</i> , 2017, 113, 23-31.	0.8	20
748	A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review. <i>Bulletin of the Menninger Clinic</i> , 2017, 81, 53-105.	0.3	15
749	Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia. <i>European Neurology</i> , 2017, 77, 231-237.	0.6	27
750	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
751	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. <i>Movement Disorders</i> , 2017, 32, 922-927.	2.2	47
752	Clinical Features and Differential Diagnosis of Parkinsonâ€™s Disease. , 2017, , 103-115.		5
753	Lewy Body Disorders. <i>Neurologic Clinics</i> , 2017, 35, 325-338.	0.8	51
754	Parkinson Symptoms in Dementia with Lewy Bodies. , 2017, , 93-109.		1
755	Accelerated Age-Dependent Hippocampal Volume Loss in Parkinson Disease With Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2017, 32, 313-319.	0.9	16

#	ARTICLE	IF	CITATIONS
756	Cognitive Behavior Therapy for Anxiety in Parkinson's Disease: Outcomes for Patients and Caregivers. <i>Clinical Gerontologist</i> , 2017, 40, 159-171.	1.2	36
757	Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 989-1018.	0.9	16
758	Immunopathology of the Nervous System. <i>Molecular and Integrative Toxicology</i> , 2017, , 123-219.	0.5	0
759	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	0.8	43
760	Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease. <i>Human Brain Mapping</i> , 2017, 38, 4716-4729.	1.9	57
761	Psychosis in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 585-622.	0.9	30
762	Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter Deficit Prodromal Cohort. <i>JAMA Neurology</i> , 2017, 74, 933.	4.5	131
763	The impact of white matter lesions on the cognitive outcome of subthalamic nucleus deep brain stimulation in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 159, 87-92.	0.6	15
764	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 55, 78-90.	1.5	48
765	Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 310-316.	0.9	84
766	Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex. <i>Movement Disorders</i> , 2017, 32, 487-497.	2.2	25
767	Parkinson's Disease: Cognitive Impairment. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 42-54.	0.4	12
768	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
769	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	4.9	394
770	Regional volumetric change in Parkinson's disease with cognitive decline. <i>Journal of the Neurological Sciences</i> , 2017, 373, 88-94.	0.3	24
771	Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2017, 36, 108-113.	0.8	16
772	A Neurophysiological Study of Semantic Processing in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 78-89.	1.2	14
773	Increased Transforming Growth Factor β 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A β 42 Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	1.2	25

#	ARTICLE	IF	CITATIONS
774	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1280-1304.	1.3	39
775	Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 840-860.	0.3	38
776	PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study. <i>Journal of the Neurological Sciences</i> , 2017, 381, 278-284.	0.3	8
777	Characterization of diplopia in non-demented patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 1-6.	1.1	20
778	Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 203-212.	0.7	16
779	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
780	Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants. <i>Journal of Neuroscience</i> , 2017, 37, 11151-11165.	1.7	100
781	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 786-801.	0.3	27
782	Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. <i>Neuroscience Letters</i> , 2017, 658, 121-132.	1.0	51
783	¹⁸ F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1888-1898.	2.8	139
784	On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivity-based single-subject classification. <i>Human Brain Mapping</i> , 2017, 38, 5845-5858.	1.9	35
785	Altered N100-potential associates with working memory impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1197-1203.	1.4	6
786	Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 56-60.	1.1	34
787	Adapted Tango for Adults With Parkinson's Disease: A Qualitative Study. <i>Adapted Physical Activity Quarterly</i> , 2017, 34, 256-275.	0.6	20
788	Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1447-1456.	2.2	34
789	Freezing of gait is associated with cognitive impairment in patients with Parkinson disease. <i>Neuroscience Letters</i> , 2017, 656, 126-130.	1.0	32
791	Modified Pfeffer Questionnaire for Functional Assessment in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 261-266.	1.2	8
792	Contribution of language studies to the understanding of cognitive impairment and its progression over time in Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 657-672.	2.9	51

#	ARTICLE	IF	CITATIONS
793	Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. <i>International Review of Neurobiology</i> , 2017, 133, 389-415.	0.9	11
794	The Lewy body dementias. , 0, , 278-300.		0
795	Latent Cognitive Phenotypes in <i>De Novo</i> Parkinsonâ€™s Disease: A Person-Centered Approach. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 551-563.	1.2	8
796	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. <i>Movement Disorders</i> , 2017, 32, 1738-1747.	2.2	43
797	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinsonâ€™s disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	2.5	29
798	Deep Brain Stimulation and Nonmotor Symptoms. <i>International Review of Neurobiology</i> , 2017, 134, 1045-1089.	0.9	20
799	Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.	1.5	30
800	Subclinical vascular disease and the risk of parkinsonism: The Rotterdam Study. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 27-32.	1.1	4
801	Cognition in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 557-583.	0.9	51
802	Î±-synuclein aggregation and its modulation. <i>International Journal of Biological Macromolecules</i> , 2017, 100, 37-54.	3.6	106
803	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 279-289.	0.6	38
804	The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. <i>Cerebellum</i> , 2017, 16, 615-622.	1.4	42
805	A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 416-423.	0.8	30
806	Molecular Imaging of Extrapyrmidal Movement Disorders. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 18-30.	2.5	4
807	Visual Hallucination and Pattern of Brain Degeneration in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 63-72.	0.8	22
808	Freezing of Gait in Parkinson's Disease: Its Pathophysiology and Pragmatic Approaches to Management. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 290-297.	0.8	26
810	Experiences of Persons With Parkinsonâ€™s Disease Engaged in Group Therapeutic Singing. <i>Journal of Music Therapy</i> , 2017, 54, 405-431.	0.6	17
811	Determination of Diffusion Weighted Magnetic Resonance Imaging Based Biomarkers of Mild Cognitive Impairment in Parkinsonâ€™s Disease. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
812	A Case Report of Psychosis in Parkinson Disease Treated with Anticholinesterase Drug. <i>Journal of Clinical Case Reports</i> , 2017, 07, .	0.0	0
813	Neuropsychiatric symptoms in untreated Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 815-826.	1.0	37
814	Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review. <i>Brain Sciences</i> , 2017, 7, 84.	1.1	31
815	Promising Effects of Neurorestorative Diets on Motor, Cognitive, and Gastrointestinal Dysfunction after Symptom Development in a Mouse Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 57.	1.7	39
816	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017, 11, 53.	1.4	7
817	Cognitive Function Characteristics of Parkinson's Disease with Sleep Disorders. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	8
818	Regional brain amyloid- β^2 accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017, 12, e0177924.	1.1	33
819	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. <i>Molecular Brain</i> , 2017, 10, 36.	1.3	25
820	A Review on Pharmacological Treatment of Idiopathic Parkinson's Disease. <i>Journal of Neurological Disorders</i> , 2017, 05, .	0.1	1
821	Correlations between CSF proteins and spontaneous neuronal activity in Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 673, 61-66.	1.0	7
822	Obstructive Sleep Apnea in Parkinson's Disease—a Mini-Review. <i>Current Sleep Medicine Reports</i> , 2018, 4, 118-124.	0.7	0
823	Risk factors for non-motor symptoms in Parkinson's disease. <i>Lancet Neurology</i> , The, 2018, 17, 559-568.	4.9	225
824	White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1139-1150.	2.2	11
825	Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 40-45.	1.1	28
826	Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease. <i>Neurology</i> , 2018, 90, e1618-e1626.	1.5	44
827	Genetic Modifiers in Neurodegeneration. <i>Current Genetic Medicine Reports</i> , 2018, 6, 11-19.	1.9	11
828	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	3.7	172
829	Memorise in the Context of Parkinson's Disease. <i>Journal of Cognitive Enhancement: Towards the Integration of Theory and Practice</i> , 2018, 2, 208-216.	0.8	3

#	ARTICLE	IF	CITATIONS
830	Office-Based Screening for Dementia in Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 704.	4.5	17
831	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	1.6	59
832	Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. <i>Brain</i> , 2018, 141, 1501-1516.	3.7	148
833	Distinct α -Synuclein strains and implications for heterogeneity among α -Synucleinopathies. <i>Neurobiology of Disease</i> , 2018, 109, 209-218.	2.1	121
834	Structural Brain Correlations of Visuospatial and Visuo-perceptual Tests in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 33-44.	1.2	25
835	Critical appraisal of pathology transmission in the α -synuclein fibril model of Lewy body disorders. <i>Experimental Neurology</i> , 2018, 299, 172-196.	2.0	33
836	An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease. <i>European Journal of Neurology</i> , 2018, 25, 148-153.	1.7	28
837	<i>APOE</i> , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
838	Factors that lead to hospitalisation in patients with Parkinson disease-A systematic review. <i>International Journal of Clinical Practice</i> , 2018, 72, e13039.	0.8	17
839	Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 297-308.	0.6	30
840	Exploring Virtual Reality for the Assessment and Rehabilitation of Executive Functions. <i>International Journal of Virtual and Augmented Reality</i> , 2018, 2, 32-47.	0.4	7
841	Research on Wind & Thermal Power Joint Bidding Strategy Considering Penalties for Wind Power's Bidding Deviation. , 2018, , .		0
842	Determination of Parkinson's disease utilizing Machine Learning Methods. , 2018, , .		3
844	Cognitive Impairment in Parkinson's Disease. <i>International Journal of School and Cognitive Psychology</i> , 2018, 05, .	0.2	0
845	α -Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis. <i>Frontiers in Neuroscience</i> , 2018, 12, 626.	1.4	28
846	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768.	2.2	17
847	The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. , 2018, 08, .		80
848	Association of visual hallucinations with very mild degenerative dementia due to dementia with Lewy bodies. <i>PLoS ONE</i> , 2018, 13, e0205909.	1.1	1

#	ARTICLE	IF	CITATIONS
849	CSF A β 1-42 level is associated with cognitive decline in early Parkinson's disease with rapid eye movement sleep behavior disorder. <i>Translational Neurodegeneration</i> , 2018, 7, 22.	3.6	12
850	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	2.2	42
851	Abnormal Spontaneous Brain Activity in Early Parkinson's Disease With Mild Cognitive Impairment: A Resting-State fMRI Study. <i>Frontiers in Physiology</i> , 2018, 9, 1093.	1.3	45
852	Candidate biomarkers for Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 699-704.	2.5	20
853	The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 477-482.	0.6	5
854	Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. , 2018, 9, 208.		14
855	Cognitive Impairment in Parkinson's Disease Is Reflected with Gradual Decrease of EEG Delta Responses during Auditory Discrimination. <i>Frontiers in Psychology</i> , 2018, 9, 170.	1.1	31
856	INDEL Length and Haplotypes in the β -Synuclein Gene: A Key to Differentiate Dementia with Lewy Bodies?1. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 207-219.	1.2	4
857	Structural and Functional Brain Patterns of Non-Motor Syndromes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 138.	1.1	37
858	Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. <i>Acta Neuropathologica</i> , 2018, 136, 589-605.	3.9	29
859	Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in ¹⁸ F-FDG PET imaging. <i>Human Brain Mapping</i> , 2018, 39, 4652-4662.	1.9	35
860	Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 621-635.	2.7	43
861	Acceptance of Cognitive Games through Smart TV Applications in Patients with Parkinson's Disease. , 2018, , .		6
862	Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 237.	1.7	11
863	Deficit in specific cognitive domains associated with dementia in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 57, 116-120.	0.8	19
864	No Significant Difference in Cognitive Decline and Mortality between Parkinson's Disease Dementia and Dementia with Lewy Bodies: Naturalistic Longitudinal Data from the Swedish Dementia Registry. <i>Journal of Parkinson's Disease</i> , 2018, 8, 553-561.	1.5	10
865	Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies. <i>Genes</i> , 2018, 9, 63.	1.0	25
866	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> , 2018, 91, e894-e905.	1.5	112

#	ARTICLE	IF	CITATIONS
867	Importance of Balance-Gait Disorder as a Risk Factor for Cognitive Impairment, Dementia and Related Non-Motor Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 539-552.	1.5	17
868	Deflating the "DBS causes personality changes" bubble. <i>Neuroethics</i> , 2021, 14, 1-17.	1.7	82
869	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019, 29, 63-74.	2.1	48
870	Association Between Migraine Headaches and Dementia in More than 7,400 Patients Followed in General Practices in the United Kingdom. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 353-360.	1.2	30
871	COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of home-based, online cognitive training on cognition and brain networks in Parkinson's disease. <i>BMC Neurology</i> , 2019, 19, 179.	0.8	11
872	Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.	1.8	28
874	Modeling of Neurodegenerative Diseases Using Discrete Chaotic Systems. <i>Communications in Theoretical Physics</i> , 2019, 71, 1241.	1.1	6
875	Co-occurrence of Convergence Insufficiency and Cognitive Impairment in Parkinsonian Disorders: A Pilot Study. <i>Frontiers in Neurology</i> , 2019, 10, 864.	1.1	4
876	Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. <i>Journal of Parkinson's Disease</i> , 2019, 9, S281-S295.	1.5	201
877	Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 309-318.	1.4	15
878	Drug treatment strategies for depression in Parkinson disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1351-1363.	0.9	61
879	Cognitive and behavioral assessment in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 613-622.	1.4	7
880	The influence of initial symptoms on phenotypes in spinocerebellar ataxia type 3. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e00719.	0.6	6
881	"Cognitive freezing": A newly recognized episodic phenomenon in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 49-54.	1.1	1
882	Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. <i>Journal of the Neurological Sciences</i> , 2019, 402, 121-130.	0.3	20
883	The effect of small vessel disease on motor and cognitive function in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2019, 182, 58-62.	0.6	35
884	Progression of Parkinson's disease patients' subtypes based on cortical thinning: 4-year follow-up. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 286-292.	1.1	27
885	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 998-1018.	0.6	82

#	ARTICLE	IF	CITATIONS
886	Mind the gaps: What we don't know about cognitive impairment in essential tremor. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 10-19.	1.1	47
887	Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 195.	1.1	15
888	Mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 897-904.	1.4	33
889	Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. <i>Drugs and Aging</i> , 2019, 36, 647-653.	1.3	19
890	Parkinson's disease: Mechanisms, translational models and management strategies. <i>Life Sciences</i> , 2019, 226, 77-90.	2.0	331
891	Impaired sleep quality and cognition in patients of Parkinson's disease with REM sleep behavior disorder: a comparative study. <i>Sleep Medicine</i> , 2019, 62, 1-5.	0.8	17
892	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. <i>Neurology</i> , 2019, 92, e1468-e1478.	1.5	16
893	Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. <i>CNS Drugs</i> , 2019, 33, 143-160.	2.7	21
894	The Role of NOX4 in Parkinson's Disease with Dementia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 696.	1.8	15
895	The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson's disease and the analysis of relevant factors. <i>Journal of Clinical Neuroscience</i> , 2019, 63, 142-148.	0.8	11
896	Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). <i>Journal of Neurology</i> , 2019, 266, 1203-1210.	1.8	14
897	Current treatment of behavioral and cognitive symptoms of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 65-73.	1.1	21
898	Long-Term Partnerships in Lewy Body Dementias. , 2019, , .		1
899	Visual Hallucinations. , 2019, , .		0
900	Cingulate cortex in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 166, 253-266.	1.0	34
901	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 139-148.	1.0	85
902	Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 183.	2.4	101
903	The impact of cognitive interventions on cognitive symptoms in idiopathic Parkinson's disease: a systematic review. <i>Aging, Neuropsychology, and Cognition</i> , 2019, 26, 637-659.	0.7	9

#	ARTICLE	IF	CITATIONS
904	Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings. <i>International Review of Neurobiology</i> , 2019, 144, 1-28.	0.9	24
905	Neuropalliative Care. , 2019, , .		16
906	Episodic recognition memory and the hippocampus in Parkinson's disease: A review. <i>Cortex</i> , 2019, 113, 191-209.	1.1	72
907	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 78-86.	2.2	58
908	Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 516-525.	2.2	42
909	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 171-179.	0.9	54
910	Care Burden and Mental Ill Health in Spouses of People With Parkinson Disease Dementia and Lewy Body Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 3-14.	1.2	26
911	Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease. <i>Applied Neuropsychology Adult</i> , 2020, 27, 431-439.	0.7	20
912	Cognitive profiles and optimal cutoffs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. <i>Psychogeriatrics</i> , 2020, 20, 20-27.	0.6	4
913	Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison. <i>Assessment</i> , 2020, 27, 1960-1970.	1.9	16
914	Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis. <i>Journal of Neurology</i> , 2020, 267, 214-227.	1.8	27
915	The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease. <i>Aging, Neuropsychology, and Cognition</i> , 2020, 27, 581-594.	0.7	17
916	Cognitive deficits in Parkinson's disease with excessive daytime sleepiness: a systematic review. <i>Aging and Mental Health</i> , 2020, 24, 1769-1780.	1.5	16
917	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. <i>Movement Disorders</i> , 2020, 35, 5-19.	2.2	60
918	Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). <i>Journal of Neural Transmission</i> , 2020, 127, 51-59.	1.4	6
919	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α -Synuclein Insult. <i>Neuron</i> , 2020, 105, 822-836.e7.	3.8	89
920	Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease. <i>Neurology</i> , 2020, 94, e718-e728.	1.5	26
921	Grey matter abnormalities are associated only with severe cognitive decline in early stages of Parkinson's disease. <i>Cortex</i> , 2020, 123, 1-11.	1.1	14

#	ARTICLE	IF	CITATIONS
922	Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 396-404.	1.3	27
923	Characterization of novel conformation-selective α -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
924	Palliative care in Parkinson's disease: review of needs assessment tools. <i>Annals of Palliative Medicine</i> , 2020, 9, S6-S15.	0.5	14
925	Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 403-412.	3.3	49
926	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 193-206.	1.5	34
927	Disentangling the Role of Working Memory in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 572037.	1.7	6
928	A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 867-879.	0.8	3
929	Anxiety: An ignored aspect of Parkinson's disease lacking attention. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110776.	2.5	34
930	Elevated caudate connectivity in cognitively normal Parkinson's disease patients. <i>Scientific Reports</i> , 2020, 10, 17978.	1.6	15
931	Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review. <i>Frontiers in Neurology</i> , 2020, 11, 531993.	1.1	43
932	<p></p>Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1841-1862.	1.3	35
933	Approach to Cognitive Impairment in Parkinson's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1495-1510.	2.1	29
934	The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: A comparison to patients with cerebral infarction. <i>PLoS ONE</i> , 2020, 15, e0236728.	1.1	9
935	Anterior insular network disconnection and cognitive impairment in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102364.	1.4	20
936	Effect of a High-Intensity Tandem Bicycle Exercise Program on Clinical Severity, Functional Magnetic Resonance Imaging, and Plasma Biomarkers in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 656.	1.1	15
937	Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. <i>Frontiers in Neurology</i> , 2020, 11, 731.	1.1	11
938	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1643-1648.	1.5	7
939	Association of slow acetylator genotype of N-acetyltransferase 2 with Parkinson's disease in south Indian population. <i>Neuroscience Letters</i> , 2020, 735, 135260.	1.0	3

#	ARTICLE	IF	CITATIONS
940	Biological Sex and Sex Hormone Impacts on Deficits in Episodic-Like Memory in a Rat Model of Early, Pre-motor Stages of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 942.	1.1	5
941	Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities. <i>Frontiers in Neurology</i> , 2020, 11, 846.	1.1	58
942	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1143-1155.	1.2	13
943	Combined subthalamic and nucleus basalis of Meynert deep brain stimulation for Parkinson's disease with dementia (DEMPARK-DBS): protocol of a randomized, sham-controlled trial. <i>Neurological Research and Practice</i> , 2020, 2, 41.	1.0	3
944	Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Neurology</i> , 2020, 11, 577874.	1.1	10
945	Staging of cognitive impairment in Parkinson's disease: validity of Quick Dementia Rating System. <i>Disability and Rehabilitation</i> , 2022, 44, 44-51.	0.9	7
946	Application of Machine Learning Technique to Distinguish Parkinson's Disease Dementia and Alzheimer's Dementia: Predictive Power of Parkinson's Disease-Related Non-Motor Symptoms and Neuropsychological Profile. <i>Journal of Personalized Medicine</i> , 2020, 10, 31.	1.1	11
947	Lewy Body Degenerations as Neuropsychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2020, 43, 361-381.	0.7	3
948	Altered awareness of motor symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 972-981.	1.3	7
949	Comment on "Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE Movement Disorders, 2020, 35, 522-522.	2.2	0
950	Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	1
951	Dementia and subthalamic deep brain stimulation in Parkinson disease. <i>Neurology</i> , 2020, 95, e384-e392.	1.5	29
952	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. <i>The Cochrane Library</i> , 2020, 2020, CD011961.	1.5	46
953	Common neurodegenerative disorders in the perioperative setting: Recommendations for screening from the Society for Perioperative Assessment and Quality Improvement (SPAQI). <i>Perioperative Care and Operating Room Management</i> , 2020, 20, 100092.	0.2	4
954	Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. <i>Brain</i> , 2020, 143, 932-943.	3.7	49
955	Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 47.	1.1	18
956	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	2.5	32
957	NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. <i>Movement Disorders</i> , 2020, 35, 640-649.	2.2	20

#	ARTICLE	IF	CITATIONS
958	The Prevalence and Determinants of Neuropsychiatric Symptoms in <scp>Lateâ€Stage</scp> Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 531-542.	0.8	24
959	Detecting the Cognitive Prodrome of Dementia in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1033-1046.	1.5	8
960	Cognition Deficits in Parkinsonâ€™s Disease: Mechanisms and Treatment. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	0.6	49
961	Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2431.	1.8	150
962	Longitudinal analysis of functional disabilities, cognitive decline and risk of dementia in women with Parkinsonâ€™s disease and detrusor overactivity. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 85-88.	0.8	2
963	Executive function networkâ€™s white matter alterations relate to Parkinsonâ€™s disease motor phenotype. <i>Neuroscience Letters</i> , 2021, 741, 135486.	1.0	4
964	Neuropathological and Biomarker Findings in Parkinsonâ€™s Disease and Alzheimerâ€™s Disease: From Protein Aggregates to Synaptic Dysfunction. <i>Journal of Parkinson's Disease</i> , 2021, 11, 107-121.	1.5	28
965	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 642-650.	2.2	41
966	Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 15-30.	1.3	13
967	Assessment of Wearing Off in Parkinsonâ€™s disease using objective measurement. <i>Journal of Neurology</i> , 2021, 268, 914-922.	1.8	16
968	Piano training enhances Stroop performance and musical self-efficacy in older adults with Parkinsonâ€™s disease. <i>Psychology of Music</i> , 2021, 49, 615-630.	0.9	11
969	Lewy Body Disease. , 2021, , 18-41.		0
971	Clinical overview and phenomenology of movement disorders. , 2021, , 1-51.e27.		3
972	Exploring Bottom-Up Visual Processing and Visual Hallucinations in Parkinson's Disease With Dementia. <i>Frontiers in Neurology</i> , 2020, 11, 579113.	1.1	4
973	APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 631145.	1.1	30
975	Neuropsychiatric Symptoms Are Associated with Dementia in Parkinson's Disease but Not Predictive of it. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 390-399.	0.8	9
976	Pharmacological validation of TDO as a target for Parkinsonâ€™s disease. <i>FEBS Journal</i> , 2021, 288, 4311-4331.	2.2	9
977	Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease. <i>Journal of Neural Transmission</i> , 2021, 128, 171-179.	1.4	13

#	ARTICLE	IF	CITATIONS
978	Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson's Disease. <i>Molecules</i> , 2021, 26, 1523.	1.7	6
979	Impact of subthreshold depression on health-related quality of life in patients with Parkinson's disease based on cognitive status. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 107.	1.0	6
980	Risk stratification for REM sleep behavior disorder in patients with Parkinson's disease: A PRISMA-compliant meta-analysis and systematic review. <i>Clinical Neurology and Neurosurgery</i> , 2021, 202, 106484.	0.6	3
981	Tablet-based patient educational interventions in care and management of complex movement disorders. <i>Disability and Rehabilitation: Assistive Technology</i> , 2021, , 1-8.	1.3	0
982	A retrospective comparison of cognitive performance in individuals with advanced Parkinson's Disease in Hong Kong and Canada. <i>Applied Neuropsychology Adult</i> , 2021, , 1-9.	0.7	0
984	Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson's disease model through inhibition of microglial activation. <i>NeuroToxicology</i> , 2021, 83, 129-136.	1.4	25
985	Clinical characteristics of Lewy body dementia in Chinese memory clinics. <i>BMC Neurology</i> , 2021, 21, 144.	0.8	14
986	Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 631584.	1.6	8
987	Meynert nucleus-related cortical thinning in Parkinson's disease with mild cognitive impairment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 1554-1566.	1.1	13
988	Meta-Analysis of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression. <i>Neuropsychology Review</i> , 2022, 32, 149-160.	2.5	24
989	Early Detection of Parkinson's and Alzheimer's Diseases using the VOT_Mean Feature. <i>Engineering, Technology & Applied Science Research</i> , 2021, 11, 6912-6918.	0.8	3
990	Potential Sex-Specific Effects of Apolipoprotein E 4 on Cognitive Decline in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 497-505.	1.5	3
991	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	1.5	5
992	Thalamic volume mediates associations between cardiorespiratory fitness (VO ₂ max) and cognition in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 19-26.	1.1	5
993	Diplopia in Parkinson's disease: Indication of a cortical phenotype with cognitive dysfunction?. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 440-449.	1.0	6
994	Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. <i>Biomedicines</i> , 2021, 9, 684.	1.4	14
995	Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Population-Based Study. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 2443-2452.	1.2	3
997	Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 690293.	1.7	32

#	ARTICLE	IF	CITATIONS
998	Progression in Parkinson's Disease: Variation in Motor and Non-motor Symptoms Severity and Predictors of Decline in Cognition, Motor Function, Disability, and Health-Related Quality of Life as Assessed by Two Different Methods. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 885-895.	0.8	14
999	Update on Major Neurocognitive Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 271-281.	0.4	1
1000	Temporal trajectory of biofluid markers in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 14820.	1.6	12
1001	Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson's disease. <i>Molecular Biology Reports</i> , 2021, 48, 5541-5548.	1.0	3
1002	Development and Validation of a Prognostic Model for Cognitive Impairment in Parkinson's Disease With REM Sleep Behavior Disorder. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 703158.	1.7	4
1003	Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease. <i>Behavioural Brain Research</i> , 2021, 410, 113349.	1.2	7
1004	Distinct progression patterns across Parkinson disease clinical subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1695-1708.	1.7	4
1005	Cognitive Reserve, Executive Function, and Memory in Parkinson's Disease. <i>Brain Sciences</i> , 2021, 11, 992.	1.1	5
1006	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110250.	2.5	18
1007	Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1917-1925.	1.5	4
1008	Different resting-state network disruptions in newly diagnosed drug-naïve Parkinson's disease patients with mild cognitive impairment. <i>BMC Neurology</i> , 2021, 21, 327.	0.8	11
1009	TrkA Signalling and Parkinson's Dementia. , 0, , .		1
1010	Abnormal Neural Activity in Different Frequency Bands in Parkinson's Disease With Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 709998.	1.7	9
1011	Pimavanserin. <i>Neurology</i> , 2021, 97, 613-614.	1.5	0
1013	Cognition, hallucination severity and hallucination-specific insight in neurodegenerative disorders and eye disease. <i>Cognitive Neuropsychiatry</i> , 2022, 27, 105-121.	0.7	4
1014	Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 656342.	1.1	4
1015	Noninvasive vagus nerve stimulation in Parkinson's disease: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021, 18, 971-984.	1.4	15
1016	Increased Mortality in Young-Onset Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2021, 14, 214-220.	0.7	9

#	ARTICLE	IF	CITATIONS
1017	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. <i>Acta Neuropathologica</i> , 2021, 142, 961-984.	3.9	31
1018	Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 665820.	1.4	14
1019	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382.	2.9	21
1020	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
1021	Tau in the Pathophysiology of Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 2179-2191.	1.1	47
1022	Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson's Disease Psychosis. <i>Journal of Applied Gerontology</i> , 2022, 41, 073346482098703.	1.0	1
1024	Exploring Virtual Reality for the Assessment and Rehabilitation of Executive Functions. , 2021, , 866-884.		0
1025	Kognitive Störungen: Koma, Delir, Demenz. , 2006, , 221-295.		8
1026	Cortico-Subcortical Dynamics in Parkinson's Disease. , 2009, , .		3
1027	Levodopa in the treatment of Parkinson's disease. , 2006, , 1-15.		64
1028	The Role of Virtual Reality in Neuropsychology: The Virtual Multiple Errands Test for the Assessment of Executive Functions in Parkinson's Disease. <i>Intelligent Systems Reference Library</i> , 2014, , 257-274.	1.0	9
1029	Alzheimer's Disease and Other Dementias. , 2005, , 853-862.		4
1030	Sleep and Cognitive Impairment. , 2017, , 73-88.		1
1031	Alzheimer Disease and Other Dementias. , 2017, , 935-943.e6.		3
1032	Alzheimer's Disease and Other Dementias. , 2011, , 1038-1047.		5
1033	Dementias. , 2012, , 1534-1582.		4
1034	Parkinson-Syndrom. , 2013, , 207-233.		1
1035	Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. <i>Lancet Neurology</i> , The, 2005, 4, 137-8.	4.9	3

#	ARTICLE	IF	CITATIONS
1036	Deep Brain Stimulation Management. , 2010, , .		9
1038	Parkinson's disease dementia and dementia with lewy bodies.. , 2015, , 227-245.		1
1039	CHAPTER 1. Parkinsonâ€™s Disease: Symptoms, Unmet Needs and New Therapeutic Targets. RSC Drug Discovery Series, 2013, , 3-25.	0.2	1
1040	Examination of Clear Speech in Parkinson Disease Using Measures of Working Vowel Space. Journal of Speech, Language, and Hearing Research, 2019, 62, 2082-2098.	0.7	19
1041	Effects of Improvisational Dance Movement Therapy on Balance and Cognition in Parkinsonâ€™s Disease. Physical and Occupational Therapy in Geriatrics, 2020, 38, 385-399.	0.2	7
1043	PDMove. , 2019, 3, 1-23.		19
1044	Psychiatric complications in Parkinson disease. American Journal of Geriatric Psychiatry, 2005, 13, 844-51.	0.6	68
1045	The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson's Disease. Psychosomatics, 2010, 51, 474-479.	2.5	132
1046	Lewy Body Dementias. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 435-463.	0.4	104
1047	The origin of motor fluctuations in Parkinsonâ€™s disease. Neurology, 2004, 62, S17-30.	1.5	157
1048	Sleep issues in Parkinsonâ€™s disease. Neurology, 2005, 64, S12-20.	1.5	121
1049	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinsonâ€™s Disease Dementia. PLoS ONE, 2012, 7, e48783.	1.1	37
1050	Neuropsychiatric Symptoms in Parkinsonâ€™s Disease Dementia Are More Similar to Alzheimerâ€™s Disease than Dementia with Lewy Bodies: A Case-Control Study. PLoS ONE, 2016, 11, e0153989.	1.1	30
1051	Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0163781.	1.1	6
1052	Propagated but Topologically Distributed Forebrain Neurons Expressing Alpha-Synuclein in Aged Macaques. PLoS ONE, 2016, 11, e0166861.	1.1	7
1053	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE, 2017, 12, e0175674.	1.1	110
1054	NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2009, , .	0.2	5
1055	Comparing Cerebral White Matter Lesion Burdens between Parkinsonâ€™s Disease with and without Dementia. Journal of Movement Disorders, 2010, 3, 6-10.	0.7	3

#	ARTICLE	IF	CITATIONS
1056	Cerebrospinal Fluid Amyloid β ₁₋₄₂ , Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2016, 9, 89-96.	0.7	22
1057	Early impairment of cognitive functions in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2007, 65, 406-410.	0.3	22
1058	Metabolic syndrome and dementia associated with Parkinson's disease: impact of age and hypertension. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 114-118.	0.3	9
1059	Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , 2012, 7, 35.	0.5	3
1060	Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1 α and BDNF/CREB pathways. <i>Ageing</i> , 2020, 12, 14897-14917.	1.4	12
1061	New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2017, 23, 731-752.	0.9	30
1062	Protective Effects of Polydatin Against Dementia-Related Disorders. <i>Current Neuropharmacology</i> , 2020, 19, 127-135.	1.4	11
1063	Functional Magnetic Resonance Imaging Biomarkers Predicting Cognitive Progression in Parkinson Disease: Protocol for a Prospective Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e12870.	0.5	4
1064	Dementia with Lewy bodies. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 333-341.	1.8	48
1065	Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. <i>Behavioural Neurology</i> , 2013, 27, 479-93.	1.1	52
1067	Nonmotor complications of Parkinson disease. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S14-S18.	0.6	22
1068	Changes of brain gray matter structure in Parkinson's disease patients with dementia. <i>Neural Regeneration Research</i> , 2013, 8, 1276-85.	1.6	11
1069	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 504-514.	1.1	178
1070	Neural Foundations of Action-related Language: Studies in Parkinson's Disease. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2018, 2018, 3-12.	0.1	1
1071	Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. <i>Psychiatry Investigation</i> , 2016, 13, 364.	0.7	1
1072	Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson's disease with w Low Educational Background. <i>Research in Neurology an International Journal</i> , 0, , 1-7.	0.0	1
1073	Parkinson's disease dementia and dementia with Lewy bodies " epidemiology, risk factors and biomarkers. <i>Norsk Epidemiologi</i> , 2012, 22, .	0.2	2
1074	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0257372.	1.1	22

#	ARTICLE	IF	CITATIONS
1076	Morbus Parkinson " Tiefe Hirnstimulation des Nucleus subthalamicus. , 2004, , 246-257.		0
1077	Management of Advanced Parkinson's Disease. , 2004, , .		0
1078	Cycad Consumption and Neurological Disease. Reviews in Food and Nutrition Toxicity, 2005, , .	0.0	0
1079	Patient Selection and Indications for Surgery. Neurological Disease and Therapy, 2005, , 27-43.	0.0	0
1081	Non-motor somatic symptoms. , 2005, , 65-78.		0
1082	Nonmotor Problems in Parkinson Disease. , 2007, , 193-204.		1
1083	D�mence � Corps de Lewy. , 2007, , 129-147.		2
1085	Entscheiden bei Morbus Parkinson " eine �bersicht. Zeitschrift f�r Neuropsychologie = Journal of Neuropsychology, 2008, 19, 235-251.	0.2	0
1086	The Characteristics of Cognitive Impairment in Parkinson's Disease and Recognition of Cognitive Symptom by Questionnaire. Journal of Movement Disorders, 2008, 1, 38-46.	0.7	0
1087	When both motion and mentation fail. , 2008, , 107-110.		0
1088	Cognitive Deficits in Parkinson's Disease. , 2009, , 1-15.		0
1089	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders. , 2009, , 17-54.		0
1090	21 Parkinson en Lewy-body-dementie (DLB). , 2009, , 231-242.		0
1092	Classification and diagnostic systems Pesach Lichtenberg and RH Belmaker. , 2009, , 501-510.		0
1093	NEUROLOGIC DISEASE AND ANESTHESIA. , 2010, , 390-399.		0
1094	Dementia with Lewy Bodies. , 2010, , 247-254.		0
1097	�s la atrofia del hipocampo en la enfermedad de Parkinson un predictor de demencia?. Alzheimer Realidades E Investigaci�n En Demencia, 2011, , 5-11.	0.1	1
1099	Non-motor signs and symptoms in Parkinson's disease. Health, 2012, 04, 1133-1137.	0.1	0

#	ARTICLE	IF	CITATIONS
1100	Signposts: What to Look for and When to Seek Help. , 2013, , 7-18.		0
1101	Management of Advanced Parkinson's Disease. , 2012, , 1051-1068.		0
1103	Management of psychosis and dementia. , 2013, , 192-224.		1
1104	The Quantitative EEG Change in Parkinson's Disease. Advances in Bioinformatics and Biomedical Engineering Book Series, 2013, , 225-234.	0.2	0
1105	Dementia with Lewy Bodies. , 2014, , 155-177.		0
1106	Scales for Measuring Parkinsonism in Demented Patients. , 2014, , 117-128.		0
1107	Yokukansan Ameliorates Psychiatric Problems in Parkinson's Disease. Juntendo Medical Journal, 2014, 60, 529-535.	0.1	0
1108	Correlation between the Seoul Neuropsychological Screening Battery of the Parkinson's Disease Patient with Mild Cognitive Impairment and Change of the Cerebral Ventricle Volume in the Brain MRI. Journal of the Korean Society of Radiology, 2014, 8, 231-240.	0.0	0
1109	Mild Cognitive Impairment in Parkinson's Disease. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 29-51.	0.3	0
1110	Parkinson-Syndrom. , 2015, , 77-102.		3
1111	Effects of Cholinesterase Inhibitors in Cognition on Parkinson's Disease Dementia: A Systematic Review and Meta-Analysis. Advances in Parkinson S Disease, 2015, 04, 90-96.	0.2	0
1112	MRI of White Matter in Dementia in Relation to Cardiovascular Risks. , 2015, , 423-433.		0
1113	Longitudinal Cerebral Perfusion Changes in Parkinson's Disease with Subjective Cognitive Impairment. Dementia and Neurocognitive Disorders, 2016, 15, 147.	0.4	3
1114	Medical Treatment of Parkinson's Disease. , 2017, , 139-156.		0
1115	Effect of clinical autonomic dysfunction on cognitive functions in Parkinson's disease. Dicle Medical Journal, 0, , 225-230.	0.2	3
1117	COGNITIVE DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE ON THE BACKGROUND OF AUTOIMMUNE PATHOLOGY. EUREKA Health Sciences, 2018, 6, 46-54.	0.1	0
1118	Parkinson Disease in a Patient with Multiple Co-morbidities. Kansas Journal of Medicine, 2016, 9, 60-61.	0.1	0
1119	Importância das manifestações motoras da Doença de Parkinson. Revista Neurociencias, 2007, 15, 51-60.	0.0	0

#	ARTICLE	IF	CITATIONS
1120	Lewy Body Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019, , 298-321.	0.1	0
1121	Cognitive Impairment in Parkinson's Disease. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2019, 56, 199-203.	0.0	0
1123	Effects of a Cycling Dual Task on Emotional Word Choice in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2019, 62, 1951-1958.	0.7	1
1124	Parkinsonism and Related Disorders. , 0, , .		0
1125	A Risk Stratification Model for Early Cognitive Impairment After Diagnosis of Parkinsonâ€™s Disease. <i>IFMBE Proceedings</i> , 2020, , 653-660.	0.2	1
1126	Body Mass Index and Brainstem Raphe Nucleus Echogenicity in <i>de novo</i> Parkinsonâ€™s Disease. <i>Journal of Neurosonology and Neuroimaging</i> , 2019, 11, 139-144.	0.0	0
1129	for Cognitive Impairment and Dementia in Parkinsonâ€™s. <i>Neuromethods</i> , 2021, , 193-225.	0.2	0
1133	A Comparative Study of the Behavioral Profile of the Behavioral Variant of Frontotemporal Dementia and Parkinsonâ€™s Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 10, 182-194.	0.6	1
1134	Cognitive Impairment and Dementia in Parkinson's Disease. <i>Psychiatric Annals</i> , 2020, 50, 100-106.	0.1	0
1135	Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 733570.	1.1	6
1136	Neurodegenerative dementia and Parkinsonism. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	1.5	0
1137	Clinical Features and Treatment of Dementia Associated With Parkinsonâ€™s Disease. , 2008, , 1-7.		0
1138	Prevention of Alzheimer disease. Encouraging evidence. <i>Canadian Family Physician</i> , 2006, 52, 200-7.	0.1	12
1139	Impaired Curve Negotiation in Drivers with Parkinson's Disease. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2009, 15, 10-18.	0.1	1
1140	Mild cognitive impairment in Parkinson's disease. <i>Minerva Medica</i> , 2011, 102, 441-59.	0.3	113
1142	Neuropsychological profile in Chinese patients with Parkinson's disease and normal global cognition according to Mini-Mental State Examination Score. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 13755-61.	1.3	2
1143	Predictors and Level of Knowledge Regarding Parkinson's Disease among Patients: A Cross-sectional Study from Thailand. <i>International Journal of Preventive Medicine</i> , 2020, 11, 25.	0.2	0
1144	What does the Dementia Rating Scale-2 measure? The relationship of neuropsychological measures to DRS-2 total and subscale scores in non-demented individuals with Parkinsonâ€™s disease. <i>Clinical Neuropsychologist</i> , 2023, 37, 174-193.	1.5	2

#	ARTICLE	IF	CITATIONS
1145	Olfactory Function and Diffusion Tensor Imaging as Markers of Mild Cognitive Impairment in Early Stages of Parkinson's Disease. <i>Clinical EEG and Neuroscience</i> , 2023, 54, 91-97.	0.9	5
1146	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12198.	1.8	6
1147	Time-course of decline in different cognitive domains in Parkinson's disease: a retrospective study. <i>Journal of Neural Transmission</i> , 2021, , 1.	1.4	0
1148	Gamified Dual-Task Training for Individuals with Parkinson Disease: An Exploratory Study on Feasibility, Safety, and Efficacy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12384.	1.2	5
1149	Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120077.	0.3	19
1150	Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 104-110.	1.1	10
1151	Cas 5. Addictions comportementales et apathie dans la maladie de Parkinson: d'un extrême à l'autre. , 2018, , 113-152.		0
1152	Quantifying test-retest reliability of repeated objective attentional measures in Lewy body dementia. <i>Journal of Neurology</i> , 2022, 269, 3605-3613.	1.8	1
1153	Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations. <i>Nature Communications</i> , 2022, 13, 519.	5.8	15
1154	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 905-916.	1.5	7
1155	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. <i>Movement Disorders</i> , 2022, 37, 713-723.	2.2	27
1156	The epidemiology of cognitive function in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 3-37.	0.9	5
1157	Homocysteine and Dementia in Parkinson Disease. , 0, , .		0
1158	Gam-COVID-Vac (Sputnik V) and Pfizer-BioNTech Vaccines Adverse Events following Immunization in Patients Affected by Parkinson's Disease and Multiple Sclerosis: A Longitudinal Study. <i>Vaccines</i> , 2022, 10, 370.	2.1	2
1159	Cognitive Dysfunction in Parkinson's Disease. , 2022, , 66-77.		0
1160	Dopamine-Related Reduction of Semantic Spreading Activation in Patients With Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 837122.	1.0	1
1161	Development and Co-design of NeuroOrb: A Novel "Serious Gaming" System Targeting Cognitive Impairment in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 728212.	1.7	1
1162	Cognitive impairment in advanced Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1163	Disrupted myelination network in the cingulate cortex of Parkinson's disease. IET Systems Biology, 2022, 16, 98-119.	0.8	9
1164	Sleep apnea and the risk of dementia: A systematic review and meta-analysis. Journal of Sleep Research, 2022, 31, e13589.	1.7	16
1165	The roles of connectivity and neuronal phenotype in determining the pattern of α -synuclein pathology in Parkinson's disease. Neurobiology of Disease, 2022, 168, 105687.	2.1	14
1166	Cognitive Impairment in Genetic Parkinson's Disease. Parkinson's Disease, 2021, 2021, 1-11.	0.6	3
1167	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. BMC Neurology, 2021, 21, 477.	0.8	7
1168	Multiple system atrophy. , 0, , 27-57.		0
1170	Clinical aspects of dementia. , 0, , 8-28.		0
1179	Patterns of dementia treatment in older adults with Parkinson's disease using nationwide medical claims data. BMC Geriatrics, 2022, 22, 353.	1.1	1
1181	Tau accelerates α -synuclein aggregation and spreading in Parkinson's disease. Brain, 2022, 145, 3454-3471.	3.7	36
1182	Path analysis of biomarkers for cognitive decline in early Parkinson's disease. PLoS ONE, 2022, 17, e0268379.	1.1	0
1183	Aquatic Therapy Intervention, Including the 4-Walls Drill, for Persons With Hoehn and Yahr Stage IV Parkinson's Disease: A Retrospective Data Analysis. , 2022, 30, 2-7.		0
1184	Accuracy of Machine Learning Using the Montreal Cognitive Assessment for the Diagnosis of Cognitive Impairment in Parkinson's Disease. Journal of Movement Disorders, 2022, 15, 132-139.	0.7	1
1185	Metabolite changes in prefrontal lobes and the anterior cingulate cortex correlate with processing speed and executive function in Parkinson disease patients. Quantitative Imaging in Medicine and Surgery, 2021, .	1.1	2
1186	Inorganic Polyphosphate, Mitochondria, and Neurodegeneration. Progress in Molecular and Subcellular Biology, 2022, , 27-49.	0.9	1
1187	Neurocognitive Disorders. , 2022, , .		0
1188	A New Instrument Combines Cognitive and Social Functioning Items for Detecting Mild Cognitive Impairment and Dementia in Parkinson's Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
1189	Basic Leucine Zipper Protein Nuclear Factor Erythroid 2-related Factor 2 as a Potential Therapeutic Target in Brain Related Disorders. Protein and Peptide Letters, 2022, 29, 676-691.	0.4	0
1190	Acetylcholine bidirectionally regulates learning and memory. Journal of Neurorestoratology, 2022, 10, 100002.	1.1	19

#	ARTICLE	IF	CITATIONS
1191	Using gait robotics to improve symptoms of Parkinson's disease: an open-label, pilot randomized controlled trial. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2022, 58, .	1.1	9
1192	Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D ₂ and Histamine H ₃ Receptors: A PET Study in Healthy Rats. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	0
1193	When to Consider Deep Brain Stimulation for Patients with Parkinson's Disease, Essential Tremor, or Dystonia. , 2022, , 88-108.		0
1194	Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. <i>BMJ Open</i> , 2022, 12, e061193.	0.8	5
1197	The impact of cognitive impairment of individuals with Parkinson's disease on their caregivers' mental health: A systematic review protocol. <i>PLoS ONE</i> , 2022, 17, e0271480.	1.1	1
1199	LRCN Based Human Activity Recognition from Video Data. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
1201	Mesenchymal stem cell-derived exosomes altered neuron cholesterol metabolism via Wnt5a-LRP1 axis and alleviated cognitive impairment in a progressive Parkinson's disease model. <i>Neuroscience Letters</i> , 2022, 787, 136810.	1.0	7
1202	When to initiate palliative care in neurology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, , 105-125.	1.0	4
1203	Emerging Roles of TREM2 in Neurodegenerative Diseases. , 2022, , 169-195.		0
1204	Abnormal Cross Frequency Coupling of Brain Electroencephalographic Oscillations Related to Visual Oddball Task in Parkinson's Disease with Mild Cognitive Impairment. <i>Clinical EEG and Neuroscience</i> , 2023, 54, 379-390.	0.9	4
1205	Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease. <i>Movement Disorders</i> , 0, , .	2.2	0
1206	Structures of α -synuclein filaments from human brains with Lewy pathology. <i>Nature</i> , 2022, 610, 791-795.	13.7	124
1207	Short and Long-Term Cognitive Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease and Identification of Relevant Factors. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2191-2209.	1.5	3
1208	Profiles of Motor-Cognitive Interference in Parkinson's Disease—The Trail-Walking-Test to Discriminate between Motor Phenotypes. <i>Brain Sciences</i> , 2022, 12, 1217.	1.1	0
1209	Neuropathological correlates of neuropsychiatric symptoms in dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 1372-1382.	0.4	16
1210	Neurochemical, histological, and behavioral profiling of the acute, subacute, and chronic MPTP mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2023, 164, 121-142.	2.1	4
1211	Developments in the mechanistic understanding and clinical application of deep brain stimulation for Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 789-803.	1.4	5
1212	Management of psychiatric and cognitive complications in Parkinson's disease. <i>BMJ, The</i> , 0, , e068718.	3.0	11

#	ARTICLE	IF	CITATIONS
1213	Community-based high-intensity cycling improves disease symptoms in individuals with Parkinson's disease: A six-month pragmatic observational study. <i>Health and Social Care in the Community</i> , 2022, 30, .	0.7	3
1214	Marked Reduction in the Risk of Dementia in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
1215	Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset. <i>Parkinsonism and Related Disorders</i> , 2022, 105, 90-95.	1.1	7
1216	Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	9
1217	Dementia and neurodegenerative disorder: An introduction. , 2023, , 1-36.		0
1220	Leczenie zaawansowanej choroby Parkinsona – rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych. , 2022, 18, 61-84.	0.1	0
1221	The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	1
1222	A Study on Some Language Impairments in Patients with Lewy Body Spectrum Disorders. <i>Zahedan Journal of Researches in Medical Sciences</i> , 2022, 25, .	0.1	0
1223	Use of computerised cognitive testing batteries in Parkinson's disease: The client's perspective. , 2006, 1, 19-22.		0
1224	Impacts of motor phenotype on cognitive function in patients with Parkinson's disease 1 year after subthalamic nucleus deep brain stimulation. <i>Geriatrics and Gerontology International</i> , 0, , .	0.7	0
1225	Differential contributions of depression, apathy, and anxiety to neuropsychological performance in Parkinson's disease versus essential tremor. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 651-664.	0.8	2
1226	Evaluating Note Frequency and Velocity During Improvised Active Music Therapy in Clients With Parkinson's Disease. <i>Journal of Music Therapy</i> , 2023, 60, 36-63.	0.6	2
1227	Novel Computer-Aided Diagnosis System for the Early Detection of Alzheimer's Disease. <i>Computers, Materials and Continua</i> , 2023, 74, 5483-5505.	1.5	0
1228	Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2023, 13, 3-23.	1.5	3
1229	Palliative care in Parkinson disease and related disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 107-128.	1.0	1
1230	A Supervised Machine Learning Approach to Classify Parkinson's Disease. , 2022, , .		0
1231	Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and		

#	ARTICLE	IF	CITATIONS
1233	Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 57-71.	1.0	6
1234	Cortical connectivity of cholinergic basal forebrain in Parkinsonâ€™s disease with mild cognitive impairment. Quantitative Imaging in Medicine and Surgery, 2023, 13, 2167-2182.	1.1	3
1235	Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinsonâ€™s disease: current evidence and future perspectives. Expert Review of Neurotherapeutics, 2023, 23, 25-43.	1.4	5
1236	Role of hippocampal subfields in neurodegenerative disease progression analyzed with a multi-scale attention-based network. NeuroImage: Clinical, 2023, 38, 103370.	1.4	3
1237	Among Gerontogens, Heavy Metals Are a Class of Their Own: A Review of the Evidence for Cellular Senescence. Brain Sciences, 2023, 13, 500.	1.1	3
1239	Allogenic microglia replacement: A novel therapeutic strategy for neurological disorders. Fundamental Research, 2023, , .	1.6	3
1240	The Relationship between Motor Symptoms, Signs, and Parkinsonism with Facial Emotion Recognition Deficits in Individuals with 22q11.2 Deletion Syndrome at High Genetic Risk for Psychosis. Acta Neurologica Scandinavica, 2023, 2023, 1-10.	1.0	0
1241	Cognitive heterogeneity in Parkinsonâ€™s disease: A mechanistic view. Neuron, 2023, 111, 1531-1546.	3.8	10
1242	Significance of clinical symptoms and red flags in early differential diagnosis of Parkinsonâ€™s disease and atypical Parkinsonian syndromes. Journal of Neural Transmission, 2023, 130, 839-846.	1.4	3
1243	Combined multidisciplinary in/outpatient rehabilitation delays definite nursing home admission in advanced Parkinsonâ€™s disease patients. Frontiers in Neurology, 0, 14, .	1.1	2
1255	Non-Motor Symptoms in Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 25-45.	0.1	2
1258	Cholinergic Imaging and Dementia. , 2023, , 127-143.		0
1278	Recent Advances in Multimodal Machine Learning for Parkinson's Disease Diagnosis: A Comprehensive Review. , 2023, , .		0